[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 484
1. Setoyama T, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Aikou T: Isolated tumour cells in blood and E-cadherin expression in oesophageal squamous cell cancer. Br J Surg; 2007 Aug;94(8):984-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated tumour cells in blood and E-cadherin expression in oesophageal squamous cell cancer.
  • BACKGROUND: Patients with oesophageal squamous cell carcinoma have a high rate of recurrence, even after curative resection.
  • The aim of this study was to examine the correlation between the presence of isolated tumour cells (ITCs) in the blood and recurrence, and between the presence of ITCs and E-cadherin expression in the primary tumour in these patients.
  • METHODS: Blood samples obtained immediately before and after resection in 125 patients with oesophageal squamous cell carcinoma were examined by real-time reverse transcription-polymerase chain reaction using carcinoembryonic antigen mRNA.
  • Blood samples from 28 healthy volunteers and 42 patients with benign diseases were used as controls.
  • ITC positivity correlated significantly with tumour depth, lymph node metastasis, stage, lymphatic invasion and venous invasion.
  • Multivariable analysis revealed that tumour depth and ITC positivity were independent factors for a shortened haematogenous disease-free interval.
  • A significant correlation was found between ITC positivity and reduced E-cadherin expression in the primary tumour (P < 0.001).
  • CONCLUSION: Examination of ITCs in the blood is useful for predicting haematogenous recurrence in patients with oesophageal squamous cell carcinoma.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Neoplastic Cells, Circulating
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 British Journal of Surgery Society Ltd.
  • (PMID = 17410638.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger
  •  go-up   go-down


2. Tandon P, Malik R, Tandon R: Congenital epulis of the newborn: a case report with review of literature. Indian J Pathol Microbiol; 2007 Jul;50(3):593-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Congenital epulis, also known as congenital gingival granular cell tumor, is a rare benign intraoral tumor found only in the new born.
  • [MeSH-major] Gingival Neoplasms / congenital. Neoplasms, Squamous Cell / congenital

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883149.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 5
  •  go-up   go-down


3. Nur S, Chuang L, Ramaswamy G: Immunohistochemical characterization of cancer antigen in uterine cancers. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1903-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ninety cases of primary uterine carcinomas (65 endometrioid [EM] carcinoma, 15 serous papillary [SP] carcinoma, 6 carcinosarcomas [malignant mixed müllerian tumors], and 4 clear cell carcinoma [CC]) and adjacent atrophic and/or hyperplastic endometrium were analyzed by IHC for CA-125 expression.
  • Squamous areas and stroma showed no staining at all.
  • In malignant mixed müllerian tumors (MMMT), the epithelial component stained as above according to the type of epithelial cell differentiation of the neoplastic cells.
  • Benign proliferative glands showed moderate apical luminal, basal, and cytoplasmic staining.
  • [MeSH-major] Adenocarcinoma / metabolism. CA-125 Antigen / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Mixed Tumor, Mullerian / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009990.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


Advertisement
4. Nishimura G, Horiuchi C, Yoshida T, Kawakami M, Yabuki K, Matsuda H, Mikami Y, Tsukuda M: Fibromatous polyp of the hypopharynx. Auris Nasus Larynx; 2006 Sep;33(3):333-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The greater part of hypopharyngeal tumors is squamous cell carcinomas, and benign tumors are really uncommon.
  • Fibromatous polyp is not thought to be a true tumor, but the symptoms are almost the same as tumorous diseases, e.g., discomfort in the throat, swallowing difficulty and respiratory distress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504437.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Soni CR, Kumar G, Sahota P, Miller DC, Litofsky NS: Metastases to Meckel's cave: report of two cases and comparative analysis of malignant tumors with meningioma and schwannoma of Meckel's cave. Clin Neurol Neurosurg; 2010 Dec;112(10):927-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 21 patients with malignant tumor involving Meckel's cave, 76% (16/21) had pain, 67% (14/21) had paraesthesia, 89% (17/21) had objective evidence of trigeminal sensory involvement and 42% (8/21) had objective evidence of trigeminal motor involvement.
  • CONCLUSION: Subtle clinical clues may help differentiate malignant from benign involvement of Meckel's cave.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / pathology. Craniotomy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Nose Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20728984.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Fernández-Aceñero MJ, Larach F, Ortega-Fernández C: Non-epithelial lesions of the larynx: review of the 10-year experience in a tertiary Spanish hospital. Acta Otolaryngol; 2009 Jan;129(1):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In all, 737 corresponded to carcinomas (726 squamous cell carcinomas).
  • We had two cases of chondrosarcoma, one case of liposarcoma, one case of synovial sarcoma, and one neural benign tumor, suggestive of neurinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Chondrosarcoma / pathology. Chondrosarcoma / radiotherapy. Chondrosarcoma / surgery. Female. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / radiotherapy. Granuloma, Plasma Cell / surgery. Humans. Liposarcoma / pathology. Liposarcoma / radiotherapy. Liposarcoma / surgery. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Neurilemmoma / pathology. Neurilemmoma / radiotherapy. Neurilemmoma / surgery. Plasmacytoma / pathology. Plasmacytoma / radiotherapy. Plasmacytoma / surgery. Retrospective Studies. Sarcoma, Synovial / pathology. Sarcoma, Synovial / radiotherapy. Sarcoma, Synovial / surgery. Spain. Vocal Cords / pathology. Vocal Cords / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607979.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


7. Chang CH, Tsai LC, Chen ST, Yuan CC, Hung MW, Hsieh BT, Chao PL, Tsai TH, Lee TW: Radioimmunotherapy and apoptotic induction on CK19-overexpressing human cervical carcinoma cells with Re-188-mAbCx-99. Anticancer Res; 2005 Jul-Aug;25(4):2719-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Using mAbCx-99, the overexpression of Ck19 protein in lysates of cell lines and tissues from various patients' cervixes were verified by immunobinding and immunoblot analysis.
  • The therapeutic effect of Re-188-mAbCx-99 on ME180 cells was examined in vitro by cell proliferation, apoptosis, DNA fragmentation and intemucleosomal levels.
  • RESULTS: A relatively high expression of Ck19 was found in all human cervical carcinoma cell lines (4- to 44-fold) and in tissue lysates (26.8- to 79-fold) from patients (31 out of 34) with cervical, endometrial or ovarian carcinomas compared with that of benign or normal control samples.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Immunotoxins / pharmacology. Keratins / biosynthesis. Radioimmunotherapy / methods. Radioisotopes / pharmacology. Rhenium / pharmacology. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Antibody Specificity. Apoptosis / radiation effects. Cell Cycle Proteins / biosynthesis. Cell Growth Processes / radiation effects. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21. Female. HeLa Cells. Humans. Nucleosomes / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Proto-Oncogene Proteins c-jun / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080517.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Immunotoxins; 0 / Nucleosomes; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-jun; 0 / Radioisotopes; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; 7440-15-5 / Rhenium
  •  go-up   go-down


8. Bonsall JM, Hughes R, Mosunjac M, Harrison D, Samady H: A rare case of squamous cell carcinoma of the bladder presenting as a metastatic right ventricular mass. Case Rep Med; 2010;2010:789609
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of squamous cell carcinoma of the bladder presenting as a metastatic right ventricular mass.
  • The pathology of a sample obtained via transvenous biopsy was consistent with squamous cell carcinoma; no primary source could initially be identified.
  • Upon autopsy, the bladder was found to contain polyps of invasive squamous cell carcinoma, similar in morphology to the tumor mass in the heart.
  • Her lungs contained multiple tumor emboli at different stages, which was likely the final cause of her death.
  • Squamous cell carcinoma metastases to the endocardium are extremely rare and without defined treatment.
  • Surgery can improve prognosis in those with primary tumors that are benign or without metastases.
  • In this case, irradiation did destroy a portion of the tumor as the final pathology showed extensive necrosis of the tumor; unfortunately, it did not change her symptoms and did not change the final outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2007 Feb;80(950):e50-3 [17495056.001]
  • [Cites] J Urol. 1987 Jan;137(1):113-4 [3795349.001]
  • [Cites] Echocardiography. 2007 Mar;24(3):286-300 [17313646.001]
  • [Cites] J Heart Valve Dis. 2002 Nov;11(6):888-90 [12479294.001]
  • [Cites] J Am Soc Echocardiogr. 2002 Dec;15(12):1541-4 [12464926.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):27-34 [17098886.001]
  • [Cites] Arq Bras Cardiol. 2006 Oct;87(4):e104-7 [17128293.001]
  • [Cites] Urology. 2006 Oct;68(4):890.e9-10 [17070384.001]
  • [Cites] J Am Soc Echocardiogr. 2006 Oct;19(10):1294.e1-3 [17000373.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Dec;53(12):645-8 [16408471.001]
  • [Cites] Lancet Oncol. 2005 Apr;6(4):219-28 [15811617.001]
  • [Cites] Acta Cardiol. 2005 Feb;60(1):73-5 [15779858.001]
  • [Cites] Acta Cardiol. 2005 Feb;60(1):57-60 [15779854.001]
  • [Cites] Vnitr Lek. 1999 Feb;45(2):118-21 [15641232.001]
  • [Cites] Am J Cardiol. 1997 Sep 1;80(5):671-82 [9295010.001]
  • [Cites] Cancer Imaging. 2007;7:19-26 [17339142.001]
  • (PMID = 20339582.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2841247
  •  go-up   go-down


9. Linecker A, Kermer C, Sulzbacher I, Angelberger P, Kletter K, Dudczak R, Ewers R, Becherer A: Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin; 2008;47(2):80-5; quiz N12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour tracer uptake was determined by standardized uptake value (SUV) normalized to body weight and /non-tumor ratios (T/N). (18)F-FDG and (18)F-FLT uptake were compared with histopathologic and immunohistochemical results.
  • RESULTS: 19 patients had malignant tumours; one patient had a benign cystadenoma (so called Warthin's tumour) of the parotid gland.
  • One negative lesion turned out to be a malignant T1 stage squamous cell carcinoma in both PET scans, the Warthin's tumour was false positive with (18)F-FDG but showed only faint uptake with (18)F-FLT, resulting in a sensitivity of 95 % for both tracers.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392317.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Fluorine Radioisotopes; 0 / Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; PG53R0DWDQ / alovudine
  •  go-up   go-down


10. Yao H, Wang H, Zhang Z, Jiang BH, Luo J, Shi X: Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer; 2008 Sep 15;123(6):1255-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.
  • Because of its ability to induce cancer cell apoptosis, it inhibits progression of benign tumors to malignant tumors and interrupts metastasis.
  • However, the effect of sulforaphane on tongue cancer cell proliferation has not yet been reported, and the mechanisms that sulforaphane inhibits cancer development are still unclear.
  • In our study, we investigated the effects of sulforaphane on expression of hypoxia-inducible factor-1alpha (HIF-1alpha), which was overexpressed in many human malignant tumors, human tongue squamous cell carcinoma and prostate cancer DU145 cells.
  • Taken together, these results suggest that sulforaphane is an effective chemopreventive compound against tongue cancers and prostate cell angiogenesis in vitro, and that the HIF-1alpha target provides a new sight into the mechanisms of sulforaphane's inhibition against tumor cell proliferation.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Hypoxia-Inducible Factor 1, alpha Subunit / drug effects. Neoplasms, Squamous Cell / metabolism. Prostatic Neoplasms / metabolism. Thiocyanates / pharmacology. Tongue Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Extracellular Signal-Regulated MAP Kinases / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression / drug effects. Humans. Isothiocyanates. MAP Kinase Kinase 4 / drug effects. MAP Kinase Kinase 4 / metabolism. Male. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / drug effects. Transfection. Vascular Endothelial Growth Factor A / drug effects. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Tongue cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18561315.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116697; United States / NCI NIH HHS / CA / R01 CA119028; United States / NIEHS NIH HHS / ES / R01 ES015375
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Isothiocyanates; 0 / Thiocyanates; 0 / Vascular Endothelial Growth Factor A; 4478-93-7 / sulforafan; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / MAP Kinase Kinase 4
  •  go-up   go-down


11. Alameda JP, Moreno-Maldonado R, Navarro M, Bravo A, Ramírez A, Page A, Jorcano JL, Fernández-Aceñero MJ, Casanova ML: An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells. Oncogene; 2010 Dec 16;29(50):6522-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells.
  • In this study, we demonstrate that the expression in tumorigenic epidermal cells of a catalytically inactive form of CYLD (CYLD(C/S)) that mimics the identified mutations of cyld in human tumors and competes with the endogenous CYLD results in enhanced cell proliferation and inhibition of apoptosis; it also stimulates cell migration and induces the expression of angiogenic factors, including vascular endothelial growth factor-A.
  • Moreover, we show the increase in malignancy of epidermal squamous cell carcinomas that express the CYLD(C/S) transgene in an in vivo xenograft model.
  • In contrast with previous studies showing the development of benign tumors by mutations in the CYLD gene, here we provide evidence that the occurrence of mutations in the CYLD gene in tumorigenic epidermal cells (carrying previous mutations) increases the aggressiveness of carcinomas, mainly through enhancement of the expression of angiogenic factors, having therefore a key role in epidermal cancer malignancy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Proliferation. Mutation. Neovascularization, Pathologic / genetics. Skin Neoplasms / blood supply. Skin Neoplasms / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Animals. Apoptosis / genetics. Cell Line, Tumor. Cell Movement / genetics. Cell Survival. Disease Progression. Humans. Mice. Mice, Nude. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20838385.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


12. Davidson T, Goitein O, Avigdor A, Zwas ST, Goshen E: 18F- FDG-PET/CT for the diagnosis of tumor thrombosis. Isr Med Assoc J; 2009 Feb;11(2):69-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F- FDG-PET/CT for the diagnosis of tumor thrombosis.
  • BACKGROUND: Venous thromboembolism is a well-recognized and relatively frequent complication of malignancy, whereas tumor thrombosis is a rare complication of solid cancers.
  • The correct diagnosis of tumor thrombosis and its differentiation from VTE can alter patient management and prevent unnecessary long-term anticoagulation treatment.
  • OBJECTIVES: To evaluate the contribution of 18F-fluorodeoxyglucose positron emission tomography/computed tomography to the diagnosis of tumor thrombosis and its differentiation from VTE.
  • METHODS: PET/CT scans from 11 patients with suspected tumor thrombosis were retrospectively evaluated.
  • RESULTS: Eight occult tumor thromboses were identified by PET/CT-positive scans.
  • Underlying pathologies included pancreatic, colorectal, renal cell, and head-neck squamous cell carcinoma, as well as lymphoma (4 patients).
  • Accuracy of PET/CT to differentiate between tumor thrombosis and benign VTE was 100% in this small study.
  • It appears that PET/CT may be helpful in the diagnosis of occult tumor thrombosis and its differentiation from VTE.

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432032.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Avilés-Izquierdo JA, Velázquez-Tarjuelo D, Lecona-Echevarría M, Lázaro-Ochaita P: [Dermoscopic features of eccrine poroma]. Actas Dermosifiliogr; 2009 Mar;100(2):133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eccrine poroma is a benign adnexal neoplasm that clinically may mimic malignant skin tumors such as squamous cell carcinoma and amelanotic melanoma.
  • Dermoscopy can improve the clinical diagnosis of this benign adnexal skin tumor.

  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445878.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Arafa M, Boniver J, Delvenne P: Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):422-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Misinterpretation especially for benign mimics results in a significant diagnostic disagreement.
  • Archival biopsies of normal ectocervical and endocervical tissues, squamous metaplasia, cervical intraepithelial neoplasia (CIN), squamous cell carcinoma, adenocarcinoma in situ, and adenocarcinoma were retrieved to perform a tissue microarray (TMA).
  • In situ hybridization signals suggesting integrated viral physical status predominated in CIN II/III, squamous cell carcinoma, and glandular (pre) neoplastic lesions.


15. Kaabipour E, Haupt HM, Stern JB, Kanetsky PA, Podolski VF, Martin AM: p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. Arch Pathol Lab Med; 2006 Jan;130(1):69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.
  • CONTEXT: Distinguishing between keratoacanthoma (KA) and squamous cell carcinoma (SCC) is not an uncommon histologic diagnostic dilemma.
  • No significant difference in measures of p16 expression was identified among the KAs, the SCCs, the indeterminate lesions, or the benign keratoses.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Keratoacanthoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Count. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Keratosis / metabolism. Keratosis / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390241.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


16. Lin C, Li J, Lu N: [Analysis of 2161 cases of neoplasm in oral maxillofacial region in Xinjiang]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Sep;45(9):553-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 2161 cases of neoplasm in oral maxillofacial region in Xinjiang].
  • OBJECTIVE: To investigate the incidence and constituent characteristic of neoplasm in oromaxillo-facial region in Xinjiang.
  • METHODS: A total of 2161 patients with benign or malignant oral-maxillofacial tumors diagnosed in Department of Dentofacial Surgery of the First Affiliated Hospital of Xinjiang Medical College from 1995 to 2009 were analyzed retrospectively.
  • RESULTS: Of the 2161 cases, 58.49% (1264/2161) was benign tumors, 33.13% (716/2161) malignant tumors, and 8.38% (181/2161) tumor-like lesions.
  • The most common benign tumors were pleomorphic adenoma, hemangioma, papilloma, adenolymphoma and ameloblastoma.
  • Squamous cell carcinoma constituted the majority of the malignant tumors.
  • CONCLUSIONS: The common pathological type of oral and maxillofacial benign neoplasm and the most common sites of malignancy in Xinjiang region were similar to those of other places inside and outside the country.
  • [MeSH-minor] Adenolymphoma. Adenoma, Pleomorphic. Ameloblastoma. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. China / epidemiology. Face. Humans. Incidence. Mouth Mucosa. Odontogenic Tumors. Retrospective Studies. Salivary Gland Neoplasms

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122451.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Wang JH, Zhang SC, Liu ZD, Chen XY, Li CY, Han Y, Ma Y: [Correlation between the mRNA levels of carcinoembryonic antigen and cytokeratin 19 in peripheral blood with staging, treatment response and prognosis in patients with lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi; 2005 Nov;28(11):773-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: CEA and CK19 mRNAs in peripheral blood were detected by Taq Man reverse transcriptase-polymerase chain reaction (RT-PCR) in 78 patients with lung cancer before and after treatment, 30 patients with benign lung diseases and 30 healthy subjects.
  • RESULTS: The positive rates of CEA mRNA and CK19 mRNA in patients with lung cancer were 69.2% (54/78) and 62.8% (49/78), respectively, which were significantly higher than those in patients with benign lung diseases and the healthy controls (P < 0.01).
  • The positive rate of CEA mRNA was the highest in adenocarcinoma, while the positive rate of CK19 mRNA was the highest in squamous cell carcinoma.
  • CONCLUSIONS: CEA and CK19 mRNAs can be used as markers in the detection of tumor micrometastases in lung cancer, and in evaluating surgical response and prognosis.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324274.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


18. Bernardini FP: Management of malignant and benign eyelid lesions. Curr Opin Ophthalmol; 2006 Oct;17(5):480-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of malignant and benign eyelid lesions.
  • PURPOSE OF REVIEW: The management of benign and malignant eyelid neoplasms has been extensively examined.
  • RECENT FINDINGS: Recent studies have focused on the results of nonsurgical approaches for benign and premalignant lesions that are routinely surgically excised.
  • In the malignant group, a consensus has been reached over the preferred method of tumor excision for basal cell carcinoma: Mohs surgery or complete surgical excision with frozen-section control of the margins offers the lowest tumor-recurrence rate.
  • Important acquisitions have been made on squamous cells for which sentinel node biopsy may reveal early metastatic cancer.
  • Intraepithelial tumor growth is a peculiar feature of sebaceous gland carcinoma that seems to indicate an increased risk for orbital invasion.
  • Recent reports regarding the rare tumor, Merkel cell carcinoma, recommend a wide surgical excision with 5 mm margins; this may reduce the incidence of lymph-node metastasis, haematogenous spread and local recurrences.
  • SUMMARY: Although treatment of the most common benign and malignant tumours affecting the eyelids has not radically changed over the years, recent reports have significantly improved the standard of care for affected patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932064.001).
  • [ISSN] 1040-8738
  • [Journal-full-title] Current opinion in ophthalmology
  • [ISO-abbreviation] Curr Opin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


19. Vigneswaran N, Beckers S, Waigel S, Mensah J, Wu J, Mo J, Fleisher KE, Bouquot J, Sacks PG, Zacharias W: Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol; 2006 Apr;80(2):147-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used an oral squamous cell carcinoma (OSCC) progression model composed of cell lines, organotypic cultures and tissue specimens to characterize EMMPRIN expression patterns by microarray analysis, qRT-PCR, Western blotting and immunohistochemistry.
  • EMMPRIN expression was limited to basal cells of normal, benign hyperkeratotic and inflammatory (lichen planus) oral mucosa.
  • Primary and metastatic OSCC showed strong cell surface expression of EMMPRIN.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell. Cell Line, Tumor. Epithelial Cells / cytology. Female. Gene Expression Profiling. Humans. Keratinocytes / cytology. Leukoplakia, Oral / pathology. Microarray Analysis. Middle Aged. Mouth Mucosa / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310185.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE13150; United States / NIDCR NIH HHS / DE / DE14395
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


20. Cai Z, Zhou Y, Lei T, Chiu JF, He QY: Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells. Cancer; 2009 Jan 1;115(1):36-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: By using proteomic technology, the authors previously observed the substantial down-regulation of mammary serine protease inhibitor (maspin) in esophageal squamous cell carcinoma and metastases.
  • In the current study, they examined the effects of maspin re-expression in a maspin-null esophageal cancer cell line EC109 and also investigated the underlying mechanism.
  • METHODS: A cell line with stable maspin expression was established.
  • The effects of maspin reintroduction on EGF-induced EMT and cell growth characteristics were evaluated.
  • RESULTS: The introduction of maspin into EC109 cells was able to inhibit EGF-induced EMT and altered cell growth characteristics, including the serum dependence, proliferative response to EGF stimulation, and colony formation ability in soft agar, indicating a conversion from a malignant phenotype to a benign phenotype.
  • This finding provides additional evidence of the tumor metastasis-suppressive activity of maspin and may indicate a new direction for future studies of the mechanism of maspin.
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Epithelial Cells. Esophageal Neoplasms. Humans. Neoplasm Metastasis / prevention & control. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 19090015.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


21. Wen SL, Zhou X, Hu HH, Peng ZZ: [Clinical characteristics of 8 cases of primary tracheal tumors]. Zhonghua Jie He He Hu Xi Za Zhi; 2009 Sep;32(9):660-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Examination by fiberoptic bronchoscopy confirmed the diagnosis of tracheal tumor in all the cases.
  • One case with benign neurinoma and 2 cases with adenoid cystic carcinomas had a long-term postoperative remission.
  • Two cases of squamous cell carcinoma with severe tracheal stenosis got rapid symptom remission after intervention of tracheal stent by fiberoptic bronchoscopy and argon plasma coagulation.
  • One patient with squamous cell carcinoma lost follow-up after surgery.
  • Benign tracheal tumors can be resected, and for some low-grade malignant tumors surgical resection and postoperative radiotherapy can improve long term survival.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079278.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Di Carlo A, Terracciano D, Mariano A, Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol; 2005 May;26(5):1363-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, several MMPs were implicated in creating an environment that supports the initiation and maintenance of tumor growth.
  • Of these patients, 22 had malignant pleural effusion, consisting of 11 breast carcinomas and 11 lung carcinomas (7 squamous cell carcinomas and 4 adenocarcinomas), and 8 patients had benign effusions.
  • The MMP-9/MMP-2 ratio was enhanced in cancer patients compared with benign diseases and healthy individuals.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Pleural Effusion / enzymology. Pleural Effusion / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15809729.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


23. Wang D, Chen S, Feng Y, Yang Q, Campbell BH, Tang X, Campbell WB: Reduced expression of 15-lipoxygenase 2 in human head and neck carcinomas. Tumour Biol; 2006;27(5):261-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we report a significant reduction of 15-lipoxygenase 2 (15-LOX-2) in seven carcinoma cell lines of the human head and neck when compared with normal primary cultured keratinocytes, and 18 primary head and neck squamous cell carcinomas (HNSCC) when compared with matched normal mucosa.
  • 15-LOX-2 is mainly expressed in the mature cells of the benign squamous epithelium, but not in the basal layer cells of benign epithelium, suggesting a role of 15-LOX-2 in cell differentiation.
  • When the effects of NSAIDs were examined on cell proliferation and regulation of 15-LOX-2 in the carcinoma cells, NS398 treatment resulted in significant growth inhibition associated with upregulation of 15-LOX-2 and its major metabolite 15-S-HETE.
  • Finally, restoration of 15-LOX-2 expression into these carcinoma cells significantly inhibited cell proliferation.
  • [MeSH-minor] Carcinoma, Squamous Cell. Cell Proliferation. Cells, Cultured. Gene Expression Regulation, Enzymologic. Humans. Keratinocytes / enzymology. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16874012.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-37981
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; EC 1.13.11.33 / ALOX15B protein, human; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase
  •  go-up   go-down


24. Souto Damin AP, Guedes Frazzon AP, de Carvalho Damin D, Beck Biehl H, Abruzzi de Oliveira L, Auler R, Marroni C, Alexandre CO: Detection of human papillomavirus DNA in squamous cell carcinoma of the esophagus by auto-nested PCR. Dis Esophagus; 2006;19(2):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human papillomavirus DNA in squamous cell carcinoma of the esophagus by auto-nested PCR.
  • The aim of the present study was to investigate the presence of human papillomavirus (HPV) in surgical specimens of esophageal squamous cell carcinoma.
  • HPV DNA was detected in 26 esophageal carcinomas (15.75%), but in none of the benign esophageal specimens (P < 0.05).
  • One tumor contained both HPV-16 and -18 DNA.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643171.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


25. Jiang B, Wu GP, Zhao YJ, Wang SC: Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol; 2008 Dec;36(12):849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcription levels of TTF-1 were detected by reverse transcription polymerase chain reaction (RT-PCR) in PEs of patients with lung cancer (56 cases) and with lung benign diseases (44 cases).
  • The expression rate of TTF-1 mRNA was significantly higher in PEs of patients with lung cancer (73.2%) than with benign lung diseases (0%).
  • In subclasses, the expression rate of TTF-1 mRNA was obviously higher in PEs of patients with PPA (93.0%) than with metastatic pulmonary adenocarcinoma (0%) and with primary pulmonary squamous cell carcinoma (12.5%).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Nuclear Proteins / genetics. Pleural Effusion, Malignant / diagnosis. RNA, Messenger / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18855882.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


26. González-García R, Rodríguez-Campo FJ, Naval-Gías L, Sastre-Pérez J, Muñoz-Guerra MF, Usandizaga JL, Díaz-González FJ: Radial forearm free flap for reconstruction of the oral cavity: clinical experience in 55 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jul;104(1):29-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the present study was to evaluate our experience with the use of the RFFF for the reconstruction of oral cavity defects after tumor resection.
  • Patients were treated for benign (n = 1) and malignant (n = 54) entities.
  • Squamous cell carcinoma was present in 54 patients.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197203.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Linkov F, Stack B, Yurkovetsky Z, Poveda S, Lokshin A, Ferris RL: Head and neck squamous and thyroid carcinomas: multiplexed Luminex approaches for early detection. Expert Opin Med Diagn; 2007 Sep;1(1):129-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck squamous and thyroid carcinomas: multiplexed Luminex approaches for early detection.
  • The most common histologic type is mucosal squamous cell carcinoma of the head and neck (SCCHN).
  • Although thyroid cancer has a generally favorable long-term outcome, its screening and diagnosis pose a challenge due to the prevalence of benign nodular thyroid disease, the rising incidence of thyroid cancer, chronicity and recurrence.
  • In the authors' published studies, it was hypothesized that an expanded panel of biomarkers comprised of cytokines, chemokines, growth factors and other tumor markers, which individually may show some promising correlation with disease status, might provide higher diagnostic power if used in combination.
  • The potential clinical role for using these technologies in follow-up, tumor surveillance to permit early identification of recurrence of SCCHN or thyroid cancer in recurrent disease or second primary tumors is discussed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23489275.001).
  • [ISSN] 1753-0059
  • [Journal-full-title] Expert opinion on medical diagnostics
  • [ISO-abbreviation] Expert Opin Med Diagn
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Li QL, Chen FJ, Zeng ZY, Yang AK, Wu QL, Zhang HZ, Hou JH: [Expression and clinical significance of VEGF-C and Flt-4 in tongue squamous cell carcinoma]. Ai Zheng; 2006 Feb;25(2):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of VEGF-C and Flt-4 in tongue squamous cell carcinoma].
  • BACKGROUND & OBJECTIVE: Vascular endothelial growth factor-C (VEGF-C) could induce lymphangiogenesis in or around solid tumor, and is closely related with lymphatic metastasis.
  • This study was to investigate the expression and clinical significance of VEGF-C and its receptor fms-like tyrosine kinase-4 (Flt-4) in tongue squamous cell carcinoma (TSCC).
  • METHODS: The expression of VEGF-C and Flt-4 in 99 specimens of TSCC and 17 specimens of benign tongue epithelial lesions was detected by LSAB immunohistochemistry.
  • RESULTS: The positive rates of VEGF-C and Flt-4 were significantly higher in TSCC than in benign tongue epithelial lesion (35.35% vs. 5.88%, and 40.40% vs. 5.88%, P<0.05).
  • CONCLUSIONS: The positive rates of VEGF-C and Flt-4 are significantly higher in TSCC than in benign tongue epithelial lesions.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Tongue Neoplasms / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-3 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Leukoplakia, Oral / metabolism. Leukoplakia, Oral / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480594.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


29. Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP: A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest; 2009 Oct;119(10):3127-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.
  • Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood.
  • We investigated this by gene expression profiling of human SKs and cutaneous squamous cell carcinomas (SCCs) and found that several genes previously connected with keratinocyte tumor development were similarly modulated in SKs and SCCs, whereas the expression of others differed by only a few fold.
  • Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression.
  • Thus,we have uncovered a positive regulatory loop between FGFR3 and FOXN1 that underlies a benign versus malignant skin tumor phenotype.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Apr 15;20(8):1028-42 [16618808.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2201-2207 [16841094.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2404-7 [16778799.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3465-71 [16849642.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):60-6 [16807070.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1268-78 [17304214.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3732-42 [17353266.001]
  • [Cites] J Invest Dermatol. 2007 Aug;127(8):1883-5 [17392824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13450-4 [17673550.001]
  • [Cites] Cell. 2007 Sep 7;130(5):932-42 [17803914.001]
  • [Cites] Differentiation. 2007 Oct;75(8):694-701 [17459087.001]
  • [Cites] World J Urol. 2007 Dec;25(6):581-93 [17912529.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):342-6 [18223206.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):1-7 [18231634.001]
  • [Cites] Curr Urol Rep. 2008 Jan;9(1):55-61 [18366975.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1243-54 [18388864.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):902-11 [18604200.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):228-33 [16552233.001]
  • [Cites] Adv Dermatol. 1999;14:307-57 [10643503.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):155-65 [10646125.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):506-10 [11286615.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] J Korean Med Sci. 2001 Oct;16(5):619-22 [11641533.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):303-9 [11841548.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):585-93 [11955951.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):288-93 [12042702.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1105-14 [12357246.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):444-51 [12778134.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):865-77 [12791271.001]
  • [Cites] Blood. 2003 Jul 15;102(2):772-3 [12835230.001]
  • [Cites] CA Cancer J Clin. 2003 Sep-Oct;53(5):292-302 [14570228.001]
  • [Cites] Nat Immunol. 2003 Nov;4(11):1128-35 [14528302.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1963-8 [14655805.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4555-62 [15231666.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4157-68 [15316080.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1187-97 [2578876.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):549-59 [7490093.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2212-21 [8804315.001]
  • [Cites] Science. 1997 Jan 17;275(5298):400-2 [8994040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3842-7 [9108066.001]
  • [Cites] Immunogenetics. 1997;46(6):509-15 [9321431.001]
  • [Cites] Trends Biochem Sci. 1998 Feb;23(2):59-62 [9538690.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Med Clin North Am. 1998 Nov;82(6):1285-307, v-vi [9889749.001]
  • [Cites] Genes Dev. 1999 Mar 1;13(5):607-19 [10072388.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):362-74 [10191051.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]
  • [Cites] Hum Mol Genet. 2005 May 1;14(9):1153-60 [15772091.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):867-76 [15854024.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [ErratumIn] J Clin Invest. 2010 Feb;120(2):6455. Pazin, Mike [corrected to Pazin, Michael J]
  • (PMID = 19729838.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR39190; United States / NCI NIH HHS / CA / CA16038; United States / NIAMS NIH HHS / AR / R01 AR045284; United States / NIAMS NIH HHS / AR / AR054856; United States / NCI NIH HHS / CA / R01 CA073796; United States / Intramural NIH HHS / / ZIA AG000378-03; United States / NIAMS NIH HHS / AR / AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR039190; United States / NIAMS NIH HHS / AR / R01 AR055218-02; United States / NCI NIH HHS / CA / P01 CA016038; United States / NCI NIH HHS / CA / CA73796; United States / NIAMS NIH HHS / AR / AR055218-02; United States / NIAMS NIH HHS / AR / AR045284; United States / NIAMS NIH HHS / AR / R01 AR055218; United States / NIAMS NIH HHS / AR / R01 AR054856
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Whn protein; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


30. Robinson JW, Brownstein S, Jordan DR, Hodge WG: Conjunctival mucoepidermoid carcinoma in a patient with ocular cicatricial pemphigoid and a review of the literature. Surv Ophthalmol; 2006 Sep-Oct;51(5):513-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive mucoepidermoid carcinoma of the conjunctiva of the left lower eyelid was diagnosed in an orbital exenteration specimen of a 57-year-old woman, after a biopsy of the same lesion was originally diagnosed as invasive squamous cell carcinoma.
  • The woman was undergoing mitomycin C injections for ocular cicatricial pemphigoid, diagnosed in the same eye 2 years prior to identification of the neoplasm.
  • The tumor invaded the cornea, sclera, lacrimal gland, regional small nerves, and lymphatics, but did not show intraocular involvement.
  • Evaluating suspected aggressive squamous cell carcinoma with special stains for mucin generally helps to identify mucoepidermoid carcinoma of the conjunctiva.
  • More extensive surgical excision than that used for squamous cell carcinoma should be implemented in the management of mucoepidermoid carcinoma of the conjunctiva to prevent recurrence.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Conjunctival Neoplasms / pathology. Conjunctivitis / complications. Pemphigoid, Benign Mucous Membrane / complications
  • [MeSH-minor] Basement Membrane / pathology. Biopsy. Drug Therapy, Combination. Female. Fluorometholone / therapeutic use. Humans. Middle Aged. Mitomycin / therapeutic use. Neoplasm Invasiveness. Ofloxacin / therapeutic use


31. Zhao Z, Huang Q, Zhao T, Zhao J: [Expression and clinical significance of PML, P53 and P16INK4A in lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):176-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The promyelocytic leukaemia (PML) protein has been implicated in control of key tumor-suppressive pathways.
  • METHODS: The tissue microarrays were created with samples from lung cancers (n=148), pulmonary benign lung tumors (n=5) and normal lung tissues (n=7), and protein expression was analyzed by immunohistochemical staining.
  • P53 expression was found in 33.3% lung cancer, and absent in benign tumors and normal tissues of the lung (P=0.038).
  • PML was negatively correlated with P53 in squamous cell carcinoma.
  • CONCLUSIONS: As an important suppressor of tumor, PML is related with P53 mutation in squamous cell carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118641.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Shao L, Newell B, Quintanilla N: Atypical fibroxanthoma and squamous cell carcinoma of the conjunctiva in xeroderma pigmentosum. Pediatr Dev Pathol; 2007 Mar-Apr;10(2):149-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical fibroxanthoma and squamous cell carcinoma of the conjunctiva in xeroderma pigmentosum.
  • The most common tumors reported in patients with XP are squamous cell carcinomas, basal cell carcinomas, and melanomas.
  • Atypical fibroxanthoma (AFX) is a pleomorphic tumor that arises predominantly in the sun-damaged skin of the head and neck regions of the elderly.
  • We describe a unique case of a 6-year-old African American boy with XP who developed an atypical fibroxanthoma and 2 squamous cell carcinomas in the conjunctiva.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Conjunctiva / pathology. Histiocytoma, Benign Fibrous / pathology. Skin Neoplasms / pathology. Xeroderma Pigmentosum / pathology
  • [MeSH-minor] African Americans. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Child, Preschool. Follow-Up Studies. Humans. Immunohistochemistry. Male. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism. Vimentin / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378688.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Tumor Suppressor Protein p53; 0 / Vimentin
  •  go-up   go-down


33. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT: Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal; 2007;21(3):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.
  • As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma.
  • Both of these benign tumors are known to be at risk of developing into cancer.
  • During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both.
  • In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma.
  • It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Chromogranin A / blood. Endometrial Neoplasms / blood. Endometriosis / blood. Leiomyoma / blood


34. Lopez-Beltran A, Cheng L, Prieto R, Blanca A, Montironi R: Lymphoepithelioma-like carcinoma of the prostate. Hum Pathol; 2009 Jul;40(7):982-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In one case the diagnosis of lymphoepithelioma-like carcinoma admixed with conventional acinar adenocarcinoma was an unexpected finding at time of transurethral resection for benign prostatic hyperplasia.
  • Microscopically, all tumors contained lymphoepithelioma-like carcinoma, which comprised 10% to 90% of the entire tumor.
  • Morphologic recognition and distinction from other prostatic lesions and tumors with prominent lymphoid stroma is critical for its clinical management.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269013.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Touloupidis S, Zisimopoulos A, Giannakopoulos S, Papatsoris AG, Kalaitzis C, Thanos A: Clinical usage of the squamous cell carcinoma antigen in patients with penile cancer. Int J Urol; 2007 Feb;14(2):174-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical usage of the squamous cell carcinoma antigen in patients with penile cancer.
  • BACKGROUND: We present our initial experience with the use of the squamous cell carcinoma (SCC) antigen (SCCAg) in 16 men with penile SCC (SCC group), in four men with condyloma acuminatum (benign group), and in 32 blood donors (control group).
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / diagnosis. Penile Neoplasms / blood. Penile Neoplasms / diagnosis. Serpins / blood

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302580.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


36. Adenis JP, Sabatier A, Robert PY: [Tumors of the eyelids in the elderly]. J Fr Ophtalmol; 2006 Jun;29(6):687-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical aspect of tumors of the eyelids is polymorphous; however, the most frequent are benign tumors such as papillomas, basal cell carcinoma, squamous cell carcinoma, meibomian gland carcinoma, and melanomas.
  • For the most malignant tumors such as malignant melanoma and Merkel cell tumor, lymph sentinel biopsy is a recent, valuable tool, but its benefit needs to be confirmed in large series.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885901.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 13
  •  go-up   go-down


37. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M: Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol; 2009 Jan;20(1):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Serum levels of YKL-40, cancer antigen 125 (CA 125), carbohydrate antigen 19-9 (CA19-9), and squamous cell carcinoma (SCC) antigen were determined by enzyme-linked immunosorbent assay in women with benign gynecologic disease (n=24), cervical malignancy (SCC, n=104; adenocarcinoma, n=37), and age-matched healthy controls (n=45).
  • Tumor-associated macrophages showed immunoreactivity for YKL-40 in 2 of 28 adenocarcinoma tissue samples, but adenocarcinoma cells themselves were nonimmunoreactive in all samples.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18723551.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adipokines; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins
  •  go-up   go-down


38. Chaichamnan K, Satayasoontorn K, Puttanupaab S, Attainsee A: Malignant proliferating trichilemmal tumors with CD34 expression. J Med Assoc Thai; 2010 Nov;93 Suppl 6:S28-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant proliferating trichilemmal tumors (MPTT) are rare neoplasm arising from outer root sheath of hair follicle, the diagnosis of which is base essentially on histological features resulting in occasionally misdiagnosis of squamous cell carcinoma.
  • In difficult cases, however evaluation of additional parameters may be needed to differentiate benign proliferating trichilemmal tumor from MPTT or differentiate PTT and MPTT from squamous cell carcinoma.
  • For comparison, concurrent proliferating trichilemmal tumors (PTT) and trichilemmal cysts (TC) as well as well-differentiated squamous cell carcinoma (SCC) were studied.
  • [MeSH-major] Antigens, CD34 / metabolism. Carcinoma, Squamous Cell / metabolism. Epidermal Cyst / pathology. Hair Follicle / pathology. Scalp / pathology. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21280514.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


39. Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R: Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis. J Clin Pathol; 2007 Jun;60(6):709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.
  • BACKGROUND: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny.
  • It is expressed in B cell non-Hodgkin's lymphoma (B-NHL), Hodgkin's lymphoma (HL) and neuroendocrine carcinomas.
  • However, its expression in other tumour types is not fully explored.
  • AIMS AND METHODS: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.
  • RESULTS: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas.
  • In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Hodgkin Disease / diagnosis. Hodgkin Disease / metabolism. Humans. Immunoenzyme Techniques. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / metabolism. Protein Array Analysis / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • [Cites] Int Urol Nephrol. 2002-2003;34(4):495-501 [14577491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Mech Dev. 1992 Nov;39(1-2):29-39 [1283313.001]
  • [Cites] Genomics. 1993 Dec;18(3):705-8 [7508415.001]
  • [Cites] C R Acad Sci III. 1995 Jan;318(1):57-66 [7757805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5709-13 [7777574.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] J Immunol. 1997 Apr 1;158(7):3197-204 [9120274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5703-8 [9159136.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):207-14 [9815975.001]
  • [Cites] Gen Physiol Biophys. 1998 Sep;17(3):211-24 [9834843.001]
  • [Cites] BJU Int. 1999 Jun;83(9):1039-44 [10368252.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):556-62 [10524622.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):459-67 [11477548.001]
  • (PMID = 16837628.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC1955074
  •  go-up   go-down


40. Salem F, Rosenblum MK, Jhanwar SC, Kancherla P, Ghossein RA, Carlson DL: Teratocarcinosarcoma of the nasal cavity and paranasal sinuses: report of 3 cases with assessment for chromosome 12p status. Hum Pathol; 2008 Apr;39(4):605-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal teratocarcinosarcoma (SNTCS) is a rare malignant neoplasm with 63 reported cases to date.
  • Two SNTCSs from the archives of Memorial Sloan-Kettering Cancer Center and one submitted from St Luke's-Roosevelt Hospital Center were evaluated by fluorescent in situ hybridization for amplification of chromosome12p, an event usually associated with the genesis of bona fide germ cell neoplasms (including mediastinal and testicular teratomas).
  • Microscopic examination revealed admixed epithelial and mesenchymal elements in all 3 cases; benign squamous and glandular epithelium and neuroepithelial tissue were identified, the squamous epithelium demonstrating "fetal-like" cytoplasmic clearing.
  • A malignant germ cell component was not identified in any of the cases.
  • Our findings suggest that 12p amplification, if it occurs at all in this setting, is exceptional and that SNTCS is a somatic-type neoplasm exhibiting divergent differentiation rather than a germ cell tumor.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284932.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Wilkins-Port CE, Ye Q, Mazurkiewicz JE, Higgins PJ: TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. Cancer Res; 2009 May 1;69(9):4081-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The phenotypic switching called epithelial-to-mesenchymal transition is frequently associated with epithelial tumor cell progression from a comparatively benign to an aggressive, invasive malignancy.
  • TGF-beta in the tumor microenvironment promotes invasive traits largely through reprogramming gene expression, which paradoxically supports matrix-disruptive as well as stabilizing processes. ras-transformed HaCaT II-4 keratinocytes undergo phenotypic changes typical of epithelial-to-mesenchymal transition, acquire a collagenolytic phenotype, and effectively invade collagen type 1 gels as a consequence of TGF-beta1 + EGF stimulation in a three-dimensional physiologically relevant model system that monitors collagen remodeling.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2000 Jan;113 Pt 2:227-35 [10633074.001]
  • [Cites] J Surg Res. 2008 May 1;146(1):32-42 [17543340.001]
  • [Cites] J Interferon Cytokine Res. 2001 Jan;21(1):11-9 [11177576.001]
  • [Cites] Jpn J Cancer Res. 2001 Mar;92(3):257-68 [11267935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6686-91 [11390996.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Biochemistry (Mosc). 2002 Jan;67(1):92-8 [11841344.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Detect Prev. 2002;26(3):222-8 [12269770.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45154-61 [12192005.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):435-48 [12649344.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):269-85 [14619979.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22595-604 [15001579.001]
  • [Cites] Exp Eye Res. 2004 Aug;79(2):263-74 [15325573.001]
  • [Cites] Oncogene. 2008 Apr 17;27(18):2626-34 [17982486.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):593-600 [18286378.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4841-53 [18427549.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1566-72 [18503039.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):3605-11 [15356104.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):558-64 [15363807.001]
  • [Cites] Ann N Y Acad Sci. 1990;580:225-32 [2186691.001]
  • [Cites] Exp Cell Res. 1991 Mar;193(1):93-100 [1995305.001]
  • [Cites] Matrix Suppl. 1992;1:368-74 [1480062.001]
  • [Cites] J Biol Chem. 1993 Aug 15;268(23):17341-7 [8349617.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4671-5 [8062262.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] EMBO J. 1995 Jul 3;14(13):2969-77 [7621813.001]
  • [Cites] Cell. 1996 Aug 23;86(4):531-42 [8752208.001]
  • [Cites] Biochem J. 1996 Dec 1;320 ( Pt 2):659-64 [8973581.001]
  • [Cites] Cell Growth Differ. 1997 Feb;8(2):243-50 [9040946.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):724-30 [9514050.001]
  • [Cites] Nat Med. 1998 Aug;4(8):923-8 [9701244.001]
  • [Cites] Mol Carcinog. 1998 Nov;23(3):144-58 [9833775.001]
  • [Cites] Biochem J. 1999 Apr 1;339 ( Pt 1):167-75 [10085241.001]
  • [Cites] Mol Biol Cell. 2004 Dec;15(12):5242-54 [15371548.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):57-66 [15720817.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2171-80 [15928670.001]
  • [Cites] J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503 [15967008.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1714-23 [15937546.001]
  • [Cites] J Cell Biochem. 2005 Aug 1;95(5):918-31 [15861394.001]
  • [Cites] Exp Cell Res. 2006 Apr 15;312(7):1093-105 [16457817.001]
  • [Cites] Front Biosci. 2006;11:3100-20 [16720379.001]
  • [Cites] Arthritis Rheum. 2006 Oct;54(10):3244-53 [17009259.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2107-14 [17119035.001]
  • [Cites] Exp Cell Res. 2007 Jul 1;313(11):2367-77 [17467690.001]
  • [Cites] Eur Urol. 2007 Sep;52(3):791-7 [17207914.001]
  • [Cites] Oncogene. 2008 Jan 24;27(5):614-28 [17637750.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1091-9 [11007946.001]
  • (PMID = 19383899.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32-HL07194; United States / NIGMS NIH HHS / GM / GM57242; United States / NIGMS NIH HHS / GM / GM057242-11; United States / NHLBI NIH HHS / HL / T32 HL007194; United States / NIGMS NIH HHS / GM / R01 GM057242; United States / NIGMS NIH HHS / GM / R01 GM057242-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Plasminogen Activator Inhibitor 1; 0 / SERPINE1 protein, human; 0 / Transforming Growth Factor beta1; 62229-50-9 / Epidermal Growth Factor; EC 3.4.21.7 / Fibrinolysin; EC 3.4.24.22 / Matrix Metalloproteinase 10; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Other-IDs] NLM/ NIHMS242077; NLM/ PMC2962982
  •  go-up   go-down


42. Ide F, Mishima K, Saito I, Kusama K: Diagnostically challenging epithelial odontogenic tumors: a selective review of 7 jawbone lesions. Head Neck Pathol; 2009 Mar;3(1):18-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other globulomaxillary lesion was managed under the erroneous diagnosis of adenomatoid odontogenic tumor and recurred 4 times over an 11-year period.
  • This tumor was found in retrospect to be consistent with an adenoid ameloblastoma with dentinoid.
  • The diagnosis of cystic squamous odontogenic tumor (SOT) occurring as a radicular lesion of an impacted lower third molar was one of exclusion.
  • Two cases of primary intraosseous squamous cell carcinoma appeared benign clinically and exhibited unexpected findings; an impacted third molar began to erupt in association with the growth of carcinoma and another periradicular carcinoma showed dentinoid formation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2009 Jan;45(1):e9-10 [18485793.001]
  • [Cites] J Oral Pathol Med. 2004 Feb;33(2):121-4 [14720199.001]
  • [Cites] J Oral Sci. 2001 Dec;43(4):287-92 [11848197.001]
  • [Cites] Virchows Arch. 2003 May;442(5):501-3 [12687356.001]
  • [Cites] Dentomaxillofac Radiol. 2004 Jan;33(1):60-2 [15140824.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Sep;62(9):1177 [15356921.001]
  • [Cites] Nihon Koku Geka Gakkai Zasshi. 1971;17(2):155-8 [5287252.001]
  • [Cites] J Oral Surg. 1974 Jun;32(6):448-51 [4524571.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1975 Nov;40(5):616-30 [1059063.001]
  • [Cites] J Oral Surg. 1977 Dec;35(12):994-6 [270569.001]
  • [Cites] Int Surg. 1978 Jan;63(1):39-42 [627459.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1982 Aug;54(2):187-96 [6956838.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1982 Nov;54(5):530-46 [6184661.001]
  • [Cites] J Oral Maxillofac Surg. 1985 Nov;43(11):888-95 [3863901.001]
  • [Cites] Int J Oral Maxillofac Surg. 1986 Feb;15(1):105-7 [3082998.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Feb;47(2):168-75 [2913253.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Mar;50(3):282-5 [1542070.001]
  • [Cites] Dentomaxillofac Radiol. 1997 Jul;26(4):214-8 [9442611.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1959 Jan;12(1):19-30 [13623159.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Nov;98(5):583-8 [15529131.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Mar;63(3):413-6 [15742299.001]
  • [Cites] Int Endod J. 2005 May;38(5):334-40 [15876298.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb;103(2):164-8 [17234529.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):229-35 [17391301.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Apr;103(4):512-5 [17095261.001]
  • [Cites] J Oral Pathol Med. 2007 Aug;36(7):383-93 [17617830.001]
  • [Cites] J Oral Pathol Med. 2007 Aug;36(7):440-3 [17617839.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Sep;104(3):368-76 [17142069.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Dec;65(12):2559-62 [18022484.001]
  • [Cites] Histopathology. 2008 Feb;52(3):299-304 [18269580.001]
  • [Cites] J Oral Pathol Med. 2008 Apr;37(4):221-7 [18221325.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Oct;106(4):e22-8 [18718792.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1613-9 [18753945.001]
  • [Cites] Histopathology. 2000 Aug;37(2):115-7 [10931233.001]
  • [Cites] J Periodontol. 2000 Aug;71(8):1365-70 [10972654.001]
  • [Cites] Histopathology. 2001 Apr;38(4):312-7 [11318896.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Jan;107(1):92-9 [19101491.001]
  • (PMID = 20596984.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  • [Other-IDs] NLM/ PMC2807539
  • [Keywords] NOTNLM ; Clinicopathologic correlation / Diagnostic pitfall / Epithelial odontogenic tumor / Jawbone
  •  go-up   go-down


43. Schaper ID, Marcuzzi GP, Weissenborn SJ, Kasper HU, Dries V, Smyth N, Fuchs P, Pfister H: Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res; 2005 Feb 15;65(4):1394-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cutaneous human papillomavirus (HPV) 8 is clearly involved in skin cancer development in epidermodysplasia verruciformis patients and its early genes E2, E6, and E7 have been implicated in cell transformation in vitro.
  • To target their expression to the basal layer of the squamous epithelia the transgenes were put under the control of the keratin-14 promoter.
  • Whereas none of the HPV8 transgene-negative littermates developed lesions in the skin or any other organ, 91% of HPV8-transgenic mice developed single or multifocal benign tumors, characterized by papillomatosis, acanthosis, hyperkeratosis, and varying degrees of epidermal dysplasia.
  • Squamous cell carcinomas developed in 6% of the transgenic FVB/N mice.
  • Whereas UV-induced mutations in the tumor suppressor gene p53 are frequently detected in human skin carcinomas, mutations in p53 were not observed either in the benign or malignant mouse tumors.


44. Wang J, Seethala RR, Zhang Q, Gooding W, van Waes C, Hasegawa H, Ferris RL: Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J Natl Cancer Inst; 2008 Apr 2;100(7):502-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The chemokine receptor 7 (CCR7) mediates survival and invasiveness of metastatic squamous cell carcinoma of the head and neck (SCCHN) to regional lymph nodes.
  • METHODS: Human SCCHN cell lines were treated with agents that block or activate CCR7-mediated signaling, and Akt activation, cell viability in the presence or absence of EGFR inhibition, and cisplatin-induced apoptosis (in the presence or absence of Akt inhibition) were assessed by immunoblotting, the MTT assay, and the detection of annexin V, respectively.
  • Expression and secretion of chemokines by primary tumors, metastatic nodes, and benign nodes of patients with SCCHN were determined by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay, respectively.
  • The role of paracrine activation of CCR7 on tumor growth was analyzed by comparing the growth of orthotopic tumors derived from B7E3 murine oral carcinoma cells in wild-type BALB/c mice, in paucity of lymphoid T cell (plt, deficient in CCL19 and CCL21 expression) mice, and in plt mice in which the implanted B7E3 cells overexpressed CCR7 (n = 14 mice per group).
  • RESULTS: In the absence of exogenous ligand treatment, blockade of CCR7 signaling reduced levels of phosphorylated (activated) Akt and decreased SCCHN cell viability by up to 59% (95% confidence interval [CI] = 58.2% to 59.8%), enhancing the effect of EGFR inhibition.
  • Metastatic nodes expressed and secreted higher levels of CCL19 than benign nodes or primary tumors.
  • CCR7-positive murine SCCHN tumors grew more slowly in plt mice than in control BALB/c mice (mean average tumor volume on day 20 = 12.2 and 26.5 mm(3), respectively; difference = 14.3 mm(3), 95% CI = 12.3 to 17.1 mm(3)).
  • CONCLUSIONS: Secretion of CCL19 and CCL21 by SCCHN cells and by paracrine sources combine to promote activation of CCR7 prosurvival signaling associated with tumor progression and disease relapse.
  • [MeSH-major] Autocrine Communication. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Chemokine CCL19 / metabolism. Chemokine CCL21 / metabolism. Head and Neck Neoplasms / metabolism. Paracrine Communication. Receptors, CCR7 / metabolism


45. D'Angelo E, Dadmanesh F, Pecorelli S, Prat J: Squamous cell carcinoma of the ovary arising from a mucinous cystic tumor of endocervical (müllerian) type. Int J Gynecol Pathol; 2010 Nov;29(6):529-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the ovary arising from a mucinous cystic tumor of endocervical (müllerian) type.
  • Primary squamous cell carcinoma of the ovary is extremely rare.
  • We studied a 58-year-old woman in whom a keratinizing squamous cell carcinoma of the ovary had arisen from a mucinous cystic tumor of endocervical (müllerian) type.
  • The tumor was interpreted initially as a transitional cell carcinoma of the ovary with marked squamous differentiation, but there was no evidence of either transitional cell carcinoma or malignant Brenner tumor.
  • The mucinous columnar epithelial component was largely benign and only focally proliferative or borderline.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cystadenoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2011 Jul;30(4):396-7 [21623198.001]
  • (PMID = 20881861.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Fukunari F, Okamura K, Zeze R, Kagawa T, Hashimoto K, Yuasa K: Cervical lymph nodes with or without metastases from oral squamous carcinoma: a correlation of MRI findings and histopathologic architecture. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jun;109(6):890-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical lymph nodes with or without metastases from oral squamous carcinoma: a correlation of MRI findings and histopathologic architecture.
  • OBJECTIVES: The aim of this study was to describe the magnetic resonance images (MRIs) of the architecture of metastatic lymph nodes as well as healthy lymph nodes and to correlate the images with the histopathologic architecture of the lymph nodes from oral squamous cell carcinoma.
  • STUDY DESIGN: The signal intensities of 98 cervical lymph nodes from 20 patients with oral squamous cell carcinoma were evaluated on T2-weighted and diffusion-weighted whole-body imaging with background body signal suppression (DWIBS).
  • RESULTS: On T2-weighted images, very hyperintense and/or isointense areas were specific findings for lymph nodes containing metastases from oral squamous cell carcinoma.
  • Using DWIBS images with inverted black-and-white image contrast, cystic degeneration, keratinization, fibrous tissue, tumor tissue, and lymphoid tissue were either hypointense or intermediate in intensity.
  • CONCLUSIONS: On T2-weighted images, very hyperintense and/or isointense areas were characteristic findings for lymph nodes containing metastases from oral squamous cell carcinoma.
  • Using DWIBS images, it was difficult to differentiate metastatic from benign lymph nodes.
  • [MeSH-major] Lymph Nodes / radiography. Lymphatic Metastasis / radiography. Magnetic Resonance Imaging. Mouth Neoplasms / pathology. Neoplasms, Squamous Cell / radiography

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20299250.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Nthumba PM: Marjolin's ulcers: theories, prognostic factors and their peculiarities in spina bifida patients. World J Surg Oncol; 2010;8:108
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The two ulcers appeared clinically benign: one was a deep ulcer, while the other was shallow; both had normal, benign-appearing edges, and a foul smelling discharge.
  • Poor prognostic features include pressure ulcer carcinomas, lesions and location in the lower limbs/trunks, all present in the two patients making their prognosis dim: this is despite the surgical margins being clear of tumor.
  • Benign appearance, induration and presence of multiple communicating sinuses are features that have not been previously described as presenting features of pressure ulcers carcinomas.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Pressure Ulcer / complications. Skin Neoplasms / etiology. Spinal Dysraphism / complications

  • Genetic Alliance. consumer health - Spina bifida.
  • MedlinePlus Health Information. consumer health - Pressure Sores.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Spina Bifida.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2000 Jan;114(1):122-6 [10620127.001]
  • [Cites] World J Surg. 2010 Oct;34(10):2272-7 [20645092.001]
  • [Cites] J South Orthop Assoc. 1999 Fall;8(3):181-7 [12132863.001]
  • [Cites] J Am Osteopath Assoc. 2003 Aug;103(8):371-5 [12956250.001]
  • [Cites] Ann Surg. 1966 Mar;163(3):445-60 [5907569.001]
  • [Cites] Plast Reconstr Surg. 1976 Jan;57(1):66-9 [1244613.001]
  • [Cites] J Bone Joint Surg Am. 1976 Dec;58(8):1146-8 [1002759.001]
  • [Cites] Ann Surg. 1981 May;193(5):598-605 [7235765.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1099-105 [4016700.001]
  • [Cites] Arch Surg. 1989 Jan;124(1):115-7 [2910238.001]
  • [Cites] J Burn Care Rehabil. 1990 Sep-Oct;11(5):460-9 [2246317.001]
  • [Cites] Dermatology. 1993;187(1):16-8 [8324271.001]
  • [Cites] South Med J. 1996 Jul;89(7):707-10 [8685758.001]
  • [Cites] J Trauma. 1997 Jan;42(1):104-7 [9003266.001]
  • [Cites] Dermatol Surg. 1998 May;24(5):561-5 [9598012.001]
  • [Cites] Cutis. 1998 Jul;62(1):49-51 [9675536.001]
  • [Cites] Lancet. 1959 Apr 11;1(7076):760-1 [13642879.001]
  • [Cites] Plast Reconstr Surg. 1963 Dec;32:649-56 [14103020.001]
  • [Cites] Burns. 2005 Jun;31(4):403-13 [15896501.001]
  • [Cites] J Burn Care Rehabil. 2001 Nov-Dec;22(6):384-9 [11761388.001]
  • (PMID = 21129225.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3014936
  •  go-up   go-down


48. Wang Z, He W, Yang G, Wang J, Wang Z, Nesland JM, Holm R, Suo Z: Decreased expression of GST pi is correlated with a poor prognosis in human esophageal squamous carcinoma. BMC Cancer; 2010;10:352
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of GST pi is correlated with a poor prognosis in human esophageal squamous carcinoma.
  • However, neither the exact role of GST pi in the pathogenesis nor its prognostic impact in squamous esophageal carcinoma is fully characterized.
  • METHODS: Immunohistochemistry was used to investigate GST pi expression on 153 archival squamous esophageal carcinoma specimens with a GST pi monoclonal antibody.
  • RESULTS: The GST pi expression was greatly reduced in tissues of esophageal carcinomas compared to adjacent normal tissues and residual benign tissues.
  • CONCLUSIONS: Our results show that GST pi expression is down regulated in the squamous esophageal carcinoma, and that the lack of GST pi expression is associated with poor prognosis.
  • Therefore, deficiency of GST pi protein expression may be an important mechanism involved in the carcinogenesis and progression of the squamous esophageal carcinoma, and the underlying mechanisms leading to decreased GST pi expression deserve further investigation.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism. Glutathione S-Transferase pi / metabolism
  • [MeSH-minor] Adult. Aged. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1993 Jul;14(7):1377-80 [8330353.001]
  • [Cites] Anticancer Res. 1993 Mar-Apr;13(2):363-8 [8517648.001]
  • [Cites] Carcinogenesis. 1996 Apr;17(4):881-4 [8625505.001]
  • [Cites] Biochem Pharmacol. 1996 Jul 26;52(2):205-12 [8694844.001]
  • [Cites] Oncology. 1997 Sep-Oct;54(5):391-9 [9260601.001]
  • [Cites] Ther Umsch. 1998 Jul;55(7):435-8 [9702113.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1998;115:290-4 [9931627.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):586-9 [9973204.001]
  • [Cites] Mol Carcinog. 1999 Feb;24(2):128-36 [10078940.001]
  • [Cites] Clin Chim Acta. 2004 Dec;350(1-2):181-8 [15530476.001]
  • [Cites] Otolaryngol Pol. 2004;58(5):895-8 [15732772.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:51-88 [15822171.001]
  • [Cites] Surg Clin North Am. 2005 Jun;85(3):649-56, xi [15927658.001]
  • [Cites] Am Fam Physician. 2006 Jun 15;73(12):2187-94 [16836035.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1427-32 [16596648.001]
  • [Cites] Mol Carcinog. 2007 Oct;46(10):839-46 [17415778.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9248-57 [17909032.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1198-209 [17919494.001]
  • [Cites] Pol Merkur Lekarski. 2007 Sep;23(135):196-9 [18080694.001]
  • [Cites] World J Gastroenterol. 2008 Jul 14;14(26):4179-84 [18636663.001]
  • [Cites] Urologe A. 2008 Sep;47(9):1205-7 [18651120.001]
  • [Cites] FEBS J. 2009 Jan;276(1):58-75 [19016852.001]
  • [Cites] Gut. 2009 Jan;58(1):5-15 [18664505.001]
  • [Cites] Am J Clin Oncol. 2009 Feb;32(1):38-43 [19194123.001]
  • [Cites] Free Radic Biol Med. 2009 May 15;46(10):1392-403 [19269317.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2009 May;296(5):H1586-97 [19270193.001]
  • [Cites] Prostate. 2009 Sep 1;69(12):1312-24 [19444856.001]
  • [Cites] World J Gastroenterol. 2009 Sep 14;15(34):4316-21 [19750576.001]
  • [Cites] Toxicology. 2009 Nov 30;265(3):122-6 [19800383.001]
  • [Cites] Biochem Soc Trans. 2010 Apr;38(2):327-30 [20298177.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2010 Apr;13(4):289-93 [20422488.001]
  • [Cites] Cancer Invest. 2010 Jun;28(5):554-9 [20210524.001]
  • [Cites] Cardiovasc Res. 2010 Jul 15;87(2):254-61 [20462865.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20859-64 [19915149.001]
  • [Cites] Head Neck. 2000 Jan;22(1):64-70 [10585607.001]
  • [Cites] Carcinogenesis. 2000 Jan;21(1):63-7 [10607735.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):310-6 [10760690.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Apr;124(4):442-7 [11283504.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Biochem J. 2001 Nov 15;360(Pt 1):1-16 [11695986.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1999 Jan;21(1):29-31 [11776791.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:135-44 [11795433.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Apr;17(4):374-81 [11982715.001]
  • [Cites] J Gastrointest Surg. 2002 May-Jun;6(3):359-67 [12022988.001]
  • [Cites] Head Neck. 2002 Jun;24(6):575-81 [12112555.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Jan;15(1):41-7 [12544693.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):319-27 [14619983.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):540-52 [14755684.001]
  • [Cites] Helv Chir Acta. 1984 Jan;50(5):541-9 [6706663.001]
  • [Cites] J Immunol. 1987 Jan 15;138(2):550-65 [2432129.001]
  • [Cites] Carcinogenesis. 1990 Jan;11(1):33-6 [2295125.001]
  • [Cites] Am J Pathol. 1990 Oct;137(4):845-53 [1977319.001]
  • [Cites] Carcinogenesis. 1995 Jul;16(7):1655-7 [7614702.001]
  • (PMID = 20602752.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  • [Other-IDs] NLM/ PMC2909209
  •  go-up   go-down


49. Chakraborty S, Swanson BJ, Bonthu N, Batra SK: Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases. J Clin Pathol; 2010 Jul;63(7):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases.
  • METHODS: A total of 330 tissue spots representing the normal skin, and benign and malignant cutaneous diseases, were analysed after staining with the monoclonal antibody to human MUC4 (clone 8G7).
  • RESULTS: While the normal epidermis showed a negative to weak-positive expression of MUC4, its expression was significantly upregulated in squamous cell carcinomas (SCCs) where the intensity of staining correlated negatively with tumour grade and positively with age.
  • Malignant melanoma, basal cell carcinoma and cutaneous cysts were negative.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] Int J Gynecol Pathol. 2009 Mar;28(2):127-33 [19188823.001]
  • [Cites] Dermatol Clin. 2000 Apr;18(2):xv-xxi [10791144.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Microbes Infect. 2002 Sep;4(11):1121-4 [12361911.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Histopathology. 1984 May;8(3):423-34 [6329942.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Dig Dis Sci. 2006 Feb;51(2):381-9 [16534686.001]
  • [Cites] J Dermatol. 2006 May;33(5):309-18 [16700662.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):556-62 [17425384.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):520-6 [18665193.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):949-56 [18781152.001]
  • [Cites] J Biosci. 2009 Mar;34(1):113-23 [19430123.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Jan;41(1):82-8 [10634605.001]
  • (PMID = 20591909.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590-13; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / R01 CA78590; United States / NCI NIH HHS / CA / P50 CA127297; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / R01 CA 133774; United States / NCI NIH HHS / CA / R01 CA133774
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS224552; NLM/ PMC2920126
  •  go-up   go-down


50. Güney M, Oral B, Demir F, Ozsoy M, Kapucuoğlu N: Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary--case report. Eur J Gynaecol Oncol; 2006;27(3):304-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary--case report.
  • Benign cystic teratoma of the ovary (BCTO) is the most common ovarian germ cell tumor occurring predominantly in early adulthood.
  • Most benign cystic teratomas with malignant transformations are squamous cell carcinomas with just 6.8% being adenocarcinomas.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800267.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


51. Mhawech-Fauceglia P, Herrmann FR, Bshara W, Odunsi K, Terracciano L, Sauter G, Cheney RT, Groth J, Penetrante R, Mhawech-Fauceglia P: Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol; 2007 Jun;60(6):694-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody.
  • BACKGROUND: Friend leukaemia integration-1 (FLI-1) antibody is a useful marker for Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET) and vascular tumours.
  • However, it is also expressed in subsets of lymphoblastic lymphoma, Merkel cell carcinoma (MCC) and desmoplastic small round cell tumour (DSRCT).
  • AIM: To determine expression of FLI-1 in various benign and malignant neoplasms, by immunohistochemical analysis on 4323 tumours using multiple tumour microarrays, as well as on whole sections.
  • RESULTS: FLI-1 was expressed in 46/62 EWS/PNETs, 2/3 olfactory neuroblastomas, 7/102 small cell carcinomas of the lung, 10/34 MCCs, 1/14 rhabdomyosarcoma, 19/132 non-Hodgkin's lymphomas, 2/3 DSRCTs, and in 53/74 benign and malignant vascular tumours.
  • In addition, 27/508 squamous cell carcinomas, 19/837 adenocarcinomas, 10/400 urothelial bladder cancers, 1/40 basal cell carcinomas, 3/29 liposarcomas, 1/40 glioblastoma multiforme and 9/29 medullar carcinomas of the breast expressed FLI-1.
  • Finally, the sensitivity and specificity of FLI-1 to distinguish EWS/PNET from other small round cell tumours (SRCTs) were 74.2% and 91.6%, respectively.
  • This finding should be kept in mind, especially when using FLI-1 as a marker for finding the primary origin of poorly differentiated metastatic tumour.
  • Finally, despite the expression of FLI-1 in numerous malignancies, it is still considered to be highly sensitive and specific in distinguishing EWS/PNET from other tumour types in general and from other SRCTs in particular.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Proto-Oncogene Protein c-fli-1 / metabolism
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / metabolism. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / metabolism. Protein Array Analysis / methods. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / metabolism. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1657-62 [11117787.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Mod Pathol. 2004 May;17(5):547-52 [15001993.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Int J Dev Biol. 1998 May;42(4):561-72 [9694627.001]
  • [Cites] Histopathology. 2005 Jun;46(6):622-34 [15910593.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1184-93 [16096408.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):151-4 [16633064.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):216-24 [10968707.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):255-60 [11556754.001]
  • (PMID = 16917000.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Protein c-fli-1
  • [Other-IDs] NLM/ PMC1955051
  •  go-up   go-down


52. Suga Y, Miyajima K, Oikawa T, Maeda J, Usuda J, Kajiwara N, Ohira T, Uchida O, Tsuboi M, Hirano T, Kato H, Ikeda N: Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer. Oncol Rep; 2008 Nov;20(5):1137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative p16 and ESR1 methylation in the peripheral blood of patients with non-small cell lung cancer.
  • Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer.
  • We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR.
  • For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; p<0.01, ESR1; p<0.001).
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. DNA Methylation. Estrogen Receptor alpha / genetics. Genes, p16. Lung Neoplasms / blood
  • [MeSH-minor] Age Factors. Aged. Carcinoembryonic Antigen / blood. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. Female. Hematologic Tests / methods. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Smoking / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949413.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / DNA, Neoplasm; 0 / Estrogen Receptor alpha; 0 / estrogen receptor alpha, human
  •  go-up   go-down


53. Díaz Molina JP, Llorente Pendas JL, Rodrigo Tapia JP, Alvarez Marcos C, Obeso Agüera S, Suárez Nieto C: [Inverted sinonasal papillomas. Review of 61 cases]. Acta Otorrinolaringol Esp; 2009 Nov-Dec;60(6):402-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Papilomas invertidos rinosinusales. Revisión de 61 casos.
  • INTRODUCTION: Inverted papillomas are benign sinonasal lesions that arise primarily from the lateral nasal wall which are characterized by their tendency to recur and propensity to be associated with malignancy.
  • The patients were studied by age, gender, site of presentation of the tumor, symptoms, radiologic studies, surgical treatment and evolution.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / epidemiology. Comorbidity. Diagnostic Imaging. Disease Progression. Female. Humans. Male. Middle Aged. Nasal Polyps / epidemiology. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Sinusitis / epidemiology. Spain / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19909715.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 24
  •  go-up   go-down


54. Park CM, Goo JM, Lee HJ, Kim MA, Lee CH, Kang MJ: Tumors in the tracheobronchial tree: CT and FDG PET features. Radiographics; 2009 Jan-Feb;29(1):55-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of tumors, including primary malignant tumors, secondary malignant tumors, and benign tumors, can occur in the tracheobronchial tree.
  • Primary malignant tumors commonly originate from the surface epithelium or the salivary glands, whereas most benign tumors arise from the mesenchymal tissue.
  • At fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET), most squamous cell carcinomas show high uptake, whereas adenoid cystic carcinoma and mucoepidermoid carcinoma show variable uptake depending on the grade of differentiation.
  • Carcinoid tumors commonly show intense enhancement at contrast material-enhanced CT, which can be helpful in making the diagnosis, and usually have lower uptake at FDG PET than would be expected for a malignant tumor.
  • Their CT manifestations are similar to those of primary malignant tumors, with uptake at FDG PET depending primarily on the metabolic activity and degree of differentiation of the primary tumor.
  • Among the benign tumors, hamartoma and lipoma can show characteristic CT findings such as "popcorn" calcification or internal fat.
  • However, CT findings in most benign tumors are nonspecific.
  • At FDG PET, benign tumors usually show little or no uptake and can be differentiated from malignant tumors.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • (PMID = 19168836.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


55. Hafezi-Bakhtiari S, Al-Habeeb A, Ghazarian D: Benign mixed tumor of the skin, hypercellular variant: a case report. J Cutan Pathol; 2010 Sep;37(9):e46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mixed tumor of the skin, hypercellular variant: a case report.
  • Microscopic examination showed a well-circumscribed dermally located tumor composed of ductal elements lined by double to multiple cell layers of bland cuboidal inner cells and elongated spindled outer cells with areas showing cribriform and solid growth patterns.
  • There are also foci of squamous differentiation as well as occasional mature adipocytes.
  • The overall morphology and immunohistochemical profile are that of a benign cutanoues mixed tumor (chondroid syringoma).
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Epidermal Cyst / diagnosis. Humans. Immunohistochemistry. Male. Scalp

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614993.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Torrente MC, Ampuero S, Abud M, Ojeda JM: Molecular detection and typing of human papillomavirus in laryngeal carcinoma specimens. Acta Otolaryngol; 2005 Aug;125(8):888-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Viral DNA was integrated into the host genome (genotype HPV 16), providing supporting evidence for a role of HPV in the carcinogenic pathway of laryngeal squamous cell carcinoma.
  • OBJECTIVE: HPV has been detected in laryngeal lesions, both benign and neoplastic, with a variable frequency (8-60%).
  • MATERIAL AND METHODS: Formalin-fixed, paraffin wax-embedded tumor samples from patients with newly diagnosed laryngeal carcinomas were collected.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Laryngeal Neoplasms / virology. Papillomaviridae / isolation & purification. Polymerase Chain Reaction / methods
  • [MeSH-minor] Aged. Aged, 80 and over. DNA, Viral / analysis. Female. Genome, Viral. Genotype. Humans. Male. Middle Aged. Neoplasm Staging. Risk Factors. Smoking

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158538.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


57. Baek HJ, Lee SJ, Cho KH, Choo HJ, Lee SM, Lee YH, Suh KJ, Moon TY, Cha JG, Yi JH, Kim MH, Jung SJ, Choi JH: Subungual tumors: clinicopathologic correlation with US and MR imaging findings. Radiographics; 2010 Oct;30(6):1621-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various types of tumors can affect the subungual space, including benign solid tumors (glomus tumor, subungual exostosis, soft-tissue chondroma, keratoacanthoma, hemangioma, lobular capillary hemangioma), benign cystic lesions (epidermal and mucoid cysts), and malignant tumors (squamous cell carcinoma, malignant melanoma).
  • Ultrasonography (US)-in particular, high-resolution US with color Doppler studies-provides useful information regarding tumor size, location, shape, and internal characteristics (cystic, solid, or mixed), but it is limited in the further characterization of tissue.
  • [MeSH-major] Bone Neoplasms / diagnosis. Glomus Tumor / diagnosis. Magnetic Resonance Imaging / methods. Nail Diseases / diagnosis. Soft Tissue Neoplasms / diagnosis. Ultrasonography / methods
  • [MeSH-minor] Chondroma / diagnosis. Chondroma / ultrasonography. Diagnosis, Differential. Epidermal Cyst / diagnosis. Epidermal Cyst / ultrasonography. Fingers. Hemangioma / diagnosis. Hemangioma / ultrasonography. Humans. Keratoacanthoma / diagnosis. Keratoacanthoma / ultrasonography. Mucoepidermoid Tumor / diagnosis. Mucoepidermoid Tumor / ultrasonography. Toes

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010.
  • (PMID = 21071379.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


58. Spannuth WA, Rocconi RP, Kirby TO, Huh WK, Conner MG: Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report. Gynecol Oncol; 2005 Jul;98(1):155-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although mature cystic teratoma is the most common tumor of the ovary, squamous cell carcinoma arising from a mature teratoma is a rare event.
  • Prognosis depends on clinical stage, grade, and recently described mode of tumor infiltration.
  • CASE: This case involves a 52-year-old woman with stage II squamous cell carcinoma arising in a mature cystic teratoma of the left ovary.
  • Final pathology demonstrated poorly differentiated squamous cell carcinoma with gamma mode of tumor infiltration.
  • CONCLUSION: Squamous cell carcinoma arising from a benign cystic teratoma is a rare event.
  • This case supports the growing evidence linking the mode of tumor infiltration with overall prognosis of survival.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922442.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Bhandarkar ND, Sims HS, David O: ProEx C stain analysis in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol; 2010 Feb;119(2):99-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We evaluated the presence and pattern of ProEx C stain, a marker for the proliferative capacity of cells, in laryngeal tissues, including benign, malignant, and recurrent respiratory papilloma (RRP) specimens, and compared it to hematoxylin and eosin staining for the presence of dysplasia.
  • RESULTS: A total of 26 specimens (9 benign, 7 malignant, 10 RRP) representing 21 patients were stained.
  • Seven of 9 benign and 7 of 10 RRP specimens stained positive.
  • The benign specimens were mostly polyps.
  • The malignant specimens were either well or moderately differentiated squamous cell carcinoma, and they stained strongly and diffusely.
  • In benign and RRP specimens, the basal layer typically stained positive.
  • Other areas of epithelium stained weakly in benign specimens and variably in RRP specimens.
  • [MeSH-major] Antigens, Neoplasm / analysis. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Papilloma / chemistry. Respiratory Tract Neoplasms / chemistry
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cell Proliferation. Diagnosis, Differential. Humans. Immunohistochemistry. Isoenzymes. Minichromosome Maintenance Complex Component 2. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20336920.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Isoenzymes; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


60. Marioni G, Pillon M, Bertolin A, Staffieri A, Marino F: The role of survivin expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma. Eur J Surg Oncol; 2007 Mar;33(2):229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of survivin expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma.
  • AIMS: Laryngeal verrucous squamous cell carcinoma (VSCC) is a highly differentiated carcinoma (SCC) whose histological diagnosis has many pitfalls in particular considering small biopsies: multiple glottic biopsies may be necessary to conclude for a malignant or benign lesion (papillary hyperplasia).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Verrucous / pathology. Glottis / pathology. Laryngeal Neoplasms / pathology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088041.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


61. Zhang P, Han Y, Huang L, Li Q, Ma D: [Expression and Clinical Significance of TTF-1 and p63 in NSCLC.]. Zhongguo Fei Ai Za Zhi; 2009 Sep 20;12(9):995-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To detect the expressions of thyroid transcription factor-1 (TTF-1) and p63 in non-small cell lung cancer (NSCLC) and to evaluate their clinical significance.
  • METHODS: The expression of TTF-1 and p63 from 404 NSCLC and 28 benign pulmonary disease (BPD) tissue specimens were detected by immunohistochemical EnVision two-step method, together with their clinicopathologic data.
  • Its sensitivity and specificity to squamous cell carcinoma (SCC) was 95.5% and 98.8%, respectively, which was positively correlated with differentiation of SCC (P=0.008), but negatively with tumor stage (P=0.002).

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719198.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Sharaf B, Levine JP, Hirsch DL, Bastidas JA, Schiff BA, Garfein ES: Importance of computer-aided design and manufacturing technology in the multidisciplinary approach to head and neck reconstruction. J Craniofac Surg; 2010 Jul;21(4):1277-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The free fibular flap is the standard method for reconstructing large mandibular defects after benign or malignant tumor ablation.
  • [MeSH-major] Ameloblastoma / surgery. Carcinoma, Squamous Cell / surgery. Computer-Aided Design. Head and Neck Neoplasms / surgery. Mandibular Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20613609.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Lui PC, Tse GM, Tan PH, Jayaram G, Putti TC, Chaiwun B, Chan NH, Lau PP, Mak KL, Khin AT: Fine-needle aspiration cytology of metaplastic carcinoma of the breast. J Clin Pathol; 2007 May;60(5):529-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metaplastic carcinoma of the breast encompasses a heterogeneous group of tumours with variable components of sarcomatoid, squamous or poorly differentiated carcinomas.
  • METHODS: 17 cases of fine-needle aspirates of histologically proven metaplastic carcinomas (4 monophasic spindle cell carcinomas, 4 squamous cell carcinomas and 11 biphasic tumours) were reviewed, with an emphasis on the presence of poorly differentiated carcinoma, squamous cell carcinoma, atypical spindle cells, benign stromal fragments and necrosis.
  • If the tumours were analysed according to the constituting components histologically, 7, 15 and 8 cases, respectively, possess poorly differentiated carcinoma cells, sarcomatoid malignant cells and squamous carcinoma cells, whereas these components were cytologically identified in 11, 10 and 7 cases, respectively.
  • Dual tumour populations were identified in only 5 of the 11 biphasic carcinomas in the cytological preparations; and the stromal material was cytologically identified in the only case with chondroid stroma.
  • The identification of dual components, unequivocal squamous carcinoma cells and chondroid stroma is helpful for diagnosis, but it is uncommon.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma, Squamous Cell / pathology. Mixed Tumor, Malignant / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Cell Differentiation. Female. Humans. Metaplasia / pathology. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1998 Jun;18(6):441-4 [9626518.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Cancer. 2000 Dec 25;90(6):342-9 [11156517.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1183-6 [11706082.001]
  • [Cites] Diagn Cytopathol. 2002 Feb;26(2):104-8 [11813328.001]
  • [Cites] Histopathology. 2002 Jan;40(1):58-64 [11903598.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):222-7 [11933267.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):677-9 [12152169.001]
  • [Cites] Acta Cytol. 2002 Sep-Oct;46(5):855-63 [12365219.001]
  • [Cites] Cancer. 2002 Dec 25;96(6):351-61 [12478683.001]
  • [Cites] Histopathology. 2003 Jan;42(1):94-5 [12493033.001]
  • [Cites] Diagn Cytopathol. 2003 Mar;28(3):153-8 [12619098.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):336-40 [12653579.001]
  • [Cites] Diagn Cytopathol. 2003 Sep;29(3):172-8 [12951688.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1506-12 [15489655.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • [Cites] Ultrastruct Pathol. 1980 Jul-Sep;1(3):337-56 [7233588.001]
  • [Cites] Am J Surg Pathol. 1983 Jan;7(1):15-27 [6829846.001]
  • [Cites] Hum Pathol. 1983 Dec;14(12):1081-2 [6642498.001]
  • [Cites] Cancer Res. 1984 May;44(5):2089-102 [6713401.001]
  • [Cites] Hum Pathol. 1984 Aug;15(8):764-7 [6745916.001]
  • [Cites] Acta Cytol. 1986 Jul-Aug;30(4):413-9 [3461650.001]
  • [Cites] Indian J Cancer. 1985 Dec;22(4):271-3 [3843092.001]
  • [Cites] Am J Surg Pathol. 1987 Dec;11(12):918-29 [2825549.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):628-35 [2544506.001]
  • [Cites] Hum Pathol. 1989 Aug;20(8):732-40 [2473024.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1490-9 [2776108.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):272-6 [2153044.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1142-50 [2227922.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):215-21 [1311889.001]
  • [Cites] Diagn Cytopathol. 1996 Jun;14(4):325-7 [8725133.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2515-25 [8952560.001]
  • [Cites] Cancer. 1997 Aug 25;81(4):228-37 [9292738.001]
  • [Cites] Pathology. 2005 Feb;37(1):84-6 [15875741.001]
  • [Cites] Diagn Cytopathol. 1999 Feb;20(2):53-6 [9951596.001]
  • (PMID = 16798932.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1994547
  •  go-up   go-down


64. Daneshbod Y, Khademi B, Moemeni B, Seif I, Daneshbod K: Preoperative washing cytology in the diagnosis of maxillary sinus lesions. Acta Cytol; 2010 Mar-Apr;54(2):148-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Over a 4-year period, 96 p tients with clinical or radiologic suspicion of a malignant maxillary sinus tumor either confined to the maxillary complex or extending to the nasal cavity underwent preoperative cytologic evaluation by sinus puncture and local washing or nasal washing.
  • RESULTS: There were 47 malignant, 42 benign and 7 borderline cases.
  • Benign lesions included inflammatory conditions (17), squamous proliferations (6), soft tissue lesions (9) and odontogenic lesions (10).
  • Malignant lesions included squamous cell carcinoma (8), sinonasal adenocarcinoma (2), salivary gland tumors (4), soft tissue tumors (18), malignant melanoma (8) and hematolymphoid neoplasms (7).
  • Diagnostic agreement between cytology and follow-up biopsy was seen mostly in benign inflammatory and odontogenic lesions and in squamous cell carcinoma and salivary gland malignancies.
  • Clusters of sloughed epithelial cells, so called Creola bodies, may be a diagnostic pitfall in benign lesions.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391970.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Bodner JC, Zitt M, Ott H, Wetscher GJ, Wykypiel H, Lucciarini P, Schmid T: Robotic-assisted thoracoscopic surgery (RATS) for benign and malignant esophageal tumors. Ann Thorac Surg; 2005 Oct;80(4):1202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted thoracoscopic surgery (RATS) for benign and malignant esophageal tumors.
  • This comprised the dissection of the intrathoracic esophagus including lymph node dissection in four patients suffering from esophageal cancer and the extirpation of a benign lesion (one leiomyoma and one foregut cyst) in the remaining two patients.
  • The median overall operating time was 173 (160-190) minutes in the oncologic cases and 121 minutes in the benign cases, including the robotic act of 147 (135-160) minutes and 94 minutes, respectively.
  • One cancer patient died after 12 months due to tumor progression and another patient had to be stented due to local tumor recurrence 19 months postoperatively.
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Carcinoma, Squamous Cell / surgery. Esophageal Cyst / surgery. Female. Follow-Up Studies. Humans. Leiomyoma / surgery. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local. Robotics / instrumentation. Robotics / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181841.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med; 2009 Aug;133(8):1317-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose.
  • CONCLUSIONS: There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653732.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


67. Haass NK, Wladykowski E, Kief S, Moll I, Brandner JM: Differential induction of connexins 26 and 30 in skin tumors and their adjacent epidermis. J Histochem Cytochem; 2006 Feb;54(2):171-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gap junctions (GJs) have been shown to play a role in tumor progression including a variety of keratinocyte-derived and non-keratinocyte-derived skin tumors.
  • Further, Cx26 and Cx30 are induced in the epidermis adjacent to malignant melanoma but absent in the epidermis adjacent to benign non-epithelial skin lesions (melanocytic nevi and angioma).
  • We further discuss the putative roles of these gap junctional proteins in tumor progression.
  • [MeSH-minor] Animals. Bowen's Disease / metabolism. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Hemangioma / metabolism. Humans. Keratinocytes / metabolism. Keratins / metabolism. Keratosis / metabolism. Liver / metabolism. Melanoma / metabolism. Mice. Mice, Inbred C57BL. Microscopy, Fluorescence. Nevus, Pigmented / metabolism. Warts / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046668.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Connexins; 0 / GJB6 protein, human; 127120-53-0 / connexin 26; 68238-35-7 / Keratins
  •  go-up   go-down


68. Livaoğlu M, Karacal N, Bektaş D, Bahadir O: Reconstruction of full-thickness nasal defect by free anterolateral thigh flap. Acta Otolaryngol; 2009 May;129(5):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All defects resulted from tumor resections.
  • Four patients had a basal cell carcinoma, one an epidermoid carcinoma, and the other patient had recurrent malignant fibrous histiocytoma.
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Histiocytoma, Benign Fibrous / surgery. Humans. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Thigh / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607893.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


69. Groenen SM, Timmers PJ, Burger CW: Recurrence rate in vulvar carcinoma in relation to pathological margin distance. Int J Gynecol Cancer; 2010 Jul;20(5):869-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: This paper describes the results of a retrospective study of surgical approaches and recurrence rates relating to patients with squamous cell carcinoma (SCC) of the vulva.
  • The data collected included clinicopathological and surgical characteristics and the following potential risk factors: pathological margin distance, less than 8 mm; stromal invasion depth, more than 2.5 mm; tumor size; and presence of benign or premalignant epithelial disorders.
  • The tumor was radically removed in 80 patients (86%), although the histopathological margin was less than 8 mm in 50 patients (54%).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / pathology. Vulva / pathology. Vulvar Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Cancer. 2011 Jul;21(5):794 [21697677.001]
  • (PMID = 20606536.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Gao HW, Ho JY, Lee HS, Yu CP: The presence of Merkel cells and CD10- and CD34-positive stromal cells compared in benign and malignant oral tumors. Oral Dis; 2009 May;15(4):259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of Merkel cells and CD10- and CD34-positive stromal cells compared in benign and malignant oral tumors.
  • BACKGROUND: To describe sequential changes in Merkel cells (MC), and CD10(+) and CD34(+) stromal cells (SC) during the transition from benign to malignant oral lesions and correlate with clinicopathologic parameters.
  • MATERIALS AND METHODS: Changes in cytokeratin 20-positive (CK20(+)) Merkel cells, CD10(+) and CD34(+) SC were immunohistochemically examined in specimens of 28 oral verrucous carcinomas (VC), 32 squamous cell carcinomas (SCC) and 36 benign squamous lesions (BSL).
  • However, the three tumor types had similar staining level and number of CD10(+) SC.
  • CONCLUSION: CD34(+) SC and to a lesser extent MC, but not CD10(+) SC, reveal statistically different density during the transition from benign to malignant oral lesions.
  • The correlations between the CD34(+) SC expression and squamous lesions may be associated with epithelial dysplasia and/or tumor invasion.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / pathology. Cell Count. Cell Transformation, Neoplastic / pathology. Chromogenic Compounds. Female. Humans. Immunohistochemistry. Keratin-20 / analysis. Male. Middle Aged. Precancerous Conditions / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220765.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Chromogenic Compounds; 0 / Keratin-20; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


71. Puizina-Ivić N, Sapunar D, Marasović D, Mirić L: An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol; 2008 Oct;32 Suppl 2:61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
  • The Bcl-2 protein has been shown to suppress cell death and protects cell against apoptosis induced by different death-inducing signals.
  • In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in the histopathological variants of the most common malignant tumors of the skin--basal cell carcinoma (BCC) and squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic keratosis (SK).
  • Bcl-2 expression in solid, adenoid and cystic variants of BCC exhibited immunoreactivity of tumor stroma with more intense staining among peripheral palisading cells.
  • Among SCC in all samples, tumor tissue lack to express Bcl-2 positivity.
  • In cases of hypertrophic and atrophic variants of AK, Bcl-2 expression was confined to basal cell layer, as well as in one case of hypertrophic variant in suprabasal cells.
  • In three histological variants of SK expresseion of Bcl-2 protein was in areas of basaloid proliferation, while in areas of squamous differentiation was negative.
  • In clonal variant immunostaining was positive among cells in characteristic "nests" Distribution of Bcl-2 protein expression in solid, adenoid and cystic variant of BCC showed that peripheral proliferating cells are protected against apoptosis what permits tumor growth.
  • In morpheaform variant reduced amount of Bcl-2 expression indicated that this variant of BCC has increased cell proliferation, and in practice shows tendency for recurrence and difficulties to eradicate.
  • Bcl-2 expression supports the observation that tumor cells are derived from basal keratinocytes.
  • In SCC, lack of Bcl-2 expression indicates that origin of tumor cells is from more differentiated suprabasal keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis, Actinic / metabolism. Keratosis, Seborrheic / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism


72. Rausch MP, Irvine KR, Antony PA, Restifo NP, Cresswell P, Hastings KT: GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. J Immunol; 2010 Sep 1;185(5):2828-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanocyte differentiation Ags, including tyrosinase-related protein (TRP) 1, are relevant to both autoimmune skin depigmentation (vitiligo) and tumor immunity, because they are expressed by both benign melanocytes and many malignant melanomas.
  • Given that many self and tumor Ags have disulfide bonds and are presented on MHC class II, GILT is likely to be important in the pathogenesis of other CD4(+) T cell-mediated autoimmune diseases and for the development of effective cancer immunotherapy.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 1990;8:531-56 [2188673.001]
  • [Cites] Cell. 1992 May 1;69(3):529-37 [1316241.001]
  • [Cites] J Exp Med. 1992 Dec 1;176(6):1693-702 [1460426.001]
  • [Cites] J Immunol. 1993 Dec 15;151(12):7284-92 [8258725.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):1965-71 [8642306.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):296-301 [9443408.001]
  • [Cites] J Exp Med. 1998 Sep 21;188(6):1203-8 [9743539.001]
  • [Cites] J Exp Med. 1998 Oct 19;188(8):1473-84 [9782124.001]
  • [Cites] Br J Dermatol. 1998 Dec;139(6):965-73 [9990357.001]
  • [Cites] J Exp Med. 1999 Mar 1;189(5):871-6 [10049951.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7 [10077623.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):709-18 [16481638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3704-9 [16505357.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3055-62 [16920942.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4369-75 [16982871.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8569-77 [17142755.001]
  • [Cites] J Invest Dermatol. 2001 Jun;116(6):891-7 [11407977.001]
  • [Cites] J Invest Dermatol. 2001 Aug;117(2):326-32 [11511311.001]
  • [Cites] Mol Biol Cell. 2001 Nov;12(11):3451-64 [11694580.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1361-5 [11701933.001]
  • [Cites] J Exp Med. 2002 May 20;195(10):1267-77 [12021307.001]
  • [Cites] Pigment Cell Res. 2002 Jun;15(3):162-73 [12028580.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):2141-7 [12165543.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5144-7 [12234976.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):6036-47 [12421991.001]
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):550-6 [12925214.001]
  • [Cites] J Immunother. 2004 Mar-Apr;27(2):79-91 [14770079.001]
  • [Cites] Bull Cancer. 1978;65(3):271-9 [102384.001]
  • [Cites] J Exp Med. 1983 Jul 1;158(1):246-51 [6345714.001]
  • [Cites] J Exp Med. 1984 Jul 1;160(1):255-69 [6204001.001]
  • [Cites] J Immunol. 1985 Jun;134(6):4226-30 [2985706.001]
  • [Cites] Arch Dermatol Res. 1985;277(4):270-5 [3923947.001]
  • [Cites] J Immunol. 1987 Feb 15;138(4):1310-6 [3100635.001]
  • [Cites] J Biol Chem. 1988 Aug 25;263(24):12036-43 [3136170.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):993-1003 [17617591.001]
  • [Cites] Traffic. 2007 Sep;8(9):1179-89 [17555533.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):8855-62 [18218638.001]
  • [Cites] Clin Vaccine Immunol. 2008 Apr;15(4):713-9 [18235043.001]
  • [Cites] Blood. 2008 Jul 15;112(2):362-73 [18354038.001]
  • [Cites] J Immunol. 2009 Jan 15;182(2):746-50 [19124716.001]
  • [Cites] J Immunol. 2010 Feb 15;184(4):1909-17 [20083666.001]
  • [Cites] J Exp Med. 2010 Mar 15;207(3):637-50 [20156971.001]
  • [Cites] J Exp Med. 2010 Mar 15;207(3):651-67 [20156973.001]
  • [Cites] J Immunol. 1999 Dec 1;163(11):5820-6 [10570265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5 [10618430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):745-50 [10639150.001]
  • [Cites] J Immunol. 2000 Apr 1;164(7):3535-42 [10725708.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):25907-14 [10852914.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):32200-7 [10915799.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22573-8 [11306582.001]
  • (PMID = 20668223.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / T32-AR007016; United States / NIAID NIH HHS / AI / R37-AI23081; United States / NCI NIH HHS / CA / R25 CA078447; United States / NIAID NIH HHS / AI / R37 AI023081; United States / NIAMS NIH HHS / AR / T32 AR007016; United States / NCI NIH HHS / CA / T32 CA09213; United States / NCI NIH HHS / CA / R25-CA078447; United States / NIAMS NIH HHS / AR / K08-AR054388; United States / NCI NIH HHS / CA / T32 CA009213; United States / NCI NIH HHS / CA / CA009213-33; United States / NIAMS NIH HHS / AR / K08 AR054388; United States / NCI NIH HHS / CA / T32 CA009213-33
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class II; 0 / Ifi30 protein, mouse; 0 / Membrane Glycoproteins; EC 1.- / Oxidoreductases; EC 1.14.18.- / Tyrp1 protein, mouse
  • [Other-IDs] NLM/ NIHMS274002; NLM/ PMC3060054
  •  go-up   go-down


73. Bukhari MH, Niazi S, Anwar M, Chaudhry NA, Naeem S: Prognostic significance of new immunohistochemistry scoring of p53 protein expression in cutaneous squamous cell carcinoma of mice. Ann N Y Acad Sci; 2008 Sep;1138:1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of new immunohistochemistry scoring of p53 protein expression in cutaneous squamous cell carcinoma of mice.
  • This study was conducted to investigate the prognostic value and therapeutic response of treatment modalities on p53 protein expression and AgNOR index in squamous cell carcinoma (SCC).
  • The newly proposed p53 IHC scoring system will help histopathologists in making their differential diagnosis among benign, premalignant, and malignant lesions.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837875.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Tumor Suppressor Protein p53; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


74. Liu DH, Wang XM, Zhang LJ, Dai SW, Liu LY, Liu JF, Wu SS, Yang SY, Fu S, Xiao XY, He DC: Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci; 2007 Feb;20(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The level and percentage of 11.6 kDa protein progressively increased with the clinical stages I-IV and were also higher in patients with squamous cell carcinoma than in other subtypes.
  • On the other hand, 11.6 kDa protein was also increased in 50% benign diseases of lung and 13% of other cancer controls.
  • [MeSH-major] Biomarkers, Tumor / blood. Lung Neoplasms / blood. Serum Amyloid A Protein / analysis
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Small Cell / blood. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Peptides / blood. Protein Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458139.001).
  • [ISSN] 0895-3988
  • [Journal-full-title] Biomedical and environmental sciences : BES
  • [ISO-abbreviation] Biomed. Environ. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 0 / Serum Amyloid A Protein
  •  go-up   go-down


75. Peng Z, Shan C, Wang H: [Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Mar;35(3):247-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Methylation-specific PCR (MSP) was used to detect the promoter methylation status of RASSF1A, p16, and DAPK genes in induced sputum and pathological tissues from 82 patients with lung cancers and 25 patients with pulmonary benign lesion.
  • The promoter methylation of RASSF1A,p16, and DAPK genes were not detected in patients with pulmonary benign lesion.
  • There was a significant difference between the lung cancer group and pulmonary benign lesion group (P<0.05).
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Lung Neoplasms / diagnosis. Sputum / metabolism. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. DNA Methylation. Death-Associated Protein Kinases. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20360646.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


76. Peschos D, Damala C, Stefanou D, Tsanou E, Assimakopoulos D, Vougiouklakis T, Charalabopoulos K, Agnantis NJ: Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol; 2006 06;21(6):603-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions.
  • They are involved in basement membrane disruption, stroma and blood vessel penetration, metastasis and more recently there is evidence that they participate in tumor growth and angiogenic events.
  • With the present study, we tried to demonstrate the expression of MMP-9 immunohistochemically, comparatively in benign, premalignant and malignant lesions of the larynx.
  • We studied 154 laryngeal lesions including 55 squamous cell carcinomas, 8 in situ carcinomas, 54 cases of dysplasia (of low and intermediate grade), 13 papillomas and 24 cases of keratosis.
  • Overexpression of MMP 9 was observed in 74.4% and 50% in invasive and in situ squamous cell carcinomas respectively.
  • In dysplastic cases, in papillomas and in keratoses the percentage of overexpression was 62.9%, 61.53% and 54.16% respectively and the expression of MMP-9 was significantly higher in invasive squamous cell carcinomas compared to dysplasias (p=0.000004).
  • The MMP-9 expression was related neither to survival nor to the other available clinicopathological parameters (tumor size, grade, clinical stage, lymph node status and patient age).
  • [MeSH-minor] Carcinoma in Situ / chemistry. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Keratosis / metabolism. Keratosis / pathology. Laryngeal Diseases / metabolism. Laryngeal Diseases / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Papilloma / chemistry. Papilloma / metabolism. Papilloma / pathology. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528670.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


77. Sheahan P, Hafidh M, Toner M, Timon C: Unexpected findings in neck dissection for squamous cell carcinoma: incidence and implications. Head Neck; 2005 Jan;27(1):28-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected findings in neck dissection for squamous cell carcinoma: incidence and implications.
  • METHODS: We retrospectively reviewed 202 consecutive patients with a preoperative diagnosis of squamous cell carcinoma (SCC), who underwent 307 neck dissections performed by a single surgeon and examined by a single pathologist.
  • These included metastatic papillary thyroid carcinoma, leukemia, lymphoma, Warthin's tumor, and tuberculosis.
  • Two of three patients with benign-appearing thyroid tissue within lymph nodes received no further treatment, and both remained well beyond 6 years.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neck Dissection
  • [MeSH-minor] Adenolymphoma / pathology. Adenolymphoma / therapy. Aged. Aged, 80 and over. Carcinoma, Papillary / pathology. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cricoid Cartilage / pathology. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphatic Metastasis. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Male. Middle Aged. Retrospective Studies. Thyroid Neoplasms / pathology. Thyroid Neoplasms / secondary. Thyroid Neoplasms / surgery. Thyroidectomy. Tuberculosis, Lymph Node / drug therapy. Tuberculosis, Lymph Node / pathology


78. Chechlinska M, Kowalewska M, Brzoska-Wojtowicz E, Radziszewski J, Ptaszynski K, Rys J, Kaminska J, Nowak R: Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma. Tumour Biol; 2010 Dec;31(6):559-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma antigen 1 and 2 expression in cultured normal peripheral blood mononuclear cells and in vulvar squamous cell carcinoma.
  • Squamous cell carcinoma antigen (SCCA) is expressed in normal squamous cell epithelia and in squamous cell carcinomas (SCC).
  • Serum levels of SCCA are elevated in patients with benign skin diseases and in patients with SCC.
  • SCCA expression level in normal PBMC is much lower than in the squamous epithelium-derived cells.
  • In VSCC, in addition to tumour itself, metastatic lymph nodes seem also to be a potential source of serum SCCA.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carcinoma, Squamous Cell / metabolism. Leukocytes, Mononuclear / metabolism. Serpins / metabolism. Vulvar Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cells, Cultured. Female. Humans. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2671-4 [16978860.001]
  • [Cites] Tumour Biol. 2006;27(3):142-52 [16641548.001]
  • [Cites] FEBS Lett. 2007 Sep 4;581(22):4260-4 [17707374.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Apr;66(1):10-20 [17964182.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):2-3 [20050335.001]
  • [Cites] J Gene Med. 2010 Jun;12(6):545-54 [20527047.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):113-22 [10653592.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):368-77 [10956412.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):347-54 [11182054.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):39-43 [11241309.001]
  • [Cites] Cancer Lett. 2001 Jun 26;167(2):205-13 [11369142.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):1987-91 [12376202.001]
  • [Cites] J Reprod Med. 2002 Sep;47(9):718-20 [12380452.001]
  • [Cites] Cytokine. 2002 Sep 21;19(6):287-96 [12421571.001]
  • [Cites] Neoplasma. 2004;51(2):103-9 [15190419.001]
  • [Cites] Cancer. 1977 Oct;40(4):1621-8 [332328.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1652-6 [2790678.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):227-32 [2807015.001]
  • [Cites] Clin Chem. 1990 Feb;36(2):251-4 [2302769.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Nov 27;181(1):51-8 [1958219.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1505-12 [2208001.001]
  • [Cites] J Am Acad Dermatol. 1990 Apr;22(4):639-42 [2319025.001]
  • [Cites] Chest. 1994 Mar;105(3):773-6 [8131539.001]
  • [Cites] J Dermatol. 1994 Feb;21(2):67-72 [8182213.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):758-64 [8625177.001]
  • [Cites] Tumour Biol. 1996;17(2):81-9 [8658017.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):1849-55 [8999871.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):75-80 [9036873.001]
  • [Cites] Biochemistry. 1998 Apr 14;37(15):5258-66 [9548757.001]
  • [Cites] Tumour Biol. 1998;19(6):517-26 [9817981.001]
  • [Cites] Int J Cancer. 1999 Oct 8;83(2):167-70 [10471522.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):9761-4 [15677460.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):904-7 [15894354.001]
  • [Cites] Clin Exp Allergy. 2005 Oct;35(10):1327-33 [16238792.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):174-81 [17291250.001]
  • (PMID = 20589490.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  • [Other-IDs] NLM/ PMC2953620
  •  go-up   go-down


79. Teerthanath S, Hariprasad S, Shri Krishna U: Primary intracystic squamous cell carcinoma of the breast: A case report and review of the literature. J Cytol; 2009 Oct;26(4):158-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intracystic squamous cell carcinoma of the breast: A case report and review of the literature.
  • Primary intracystic squamous cell carcinoma (SCC) of the breast is an extremely rare entity and has a low incidence in comparison with other breast cancers.
  • Cytological smears of the fluid aspirated from the breast tumor revealed malignant squamous cells dispersed in single and occasional groups along with numerous cyst macrophages, suggesting cystic SCC.
  • Although the presence of abundant foamy macrophages in the background of fine needle aspiration cytology smears of the breast suggest benign breast lesion, when associated with malignant squamous cells, these suggest cystic primary SCC or metastatic SCC.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 2000 Jun;30(6):279-82 [10939434.001]
  • [Cites] Acta Cytol. 2003 Jan-Feb;47(1):27-35 [12585027.001]
  • [Cites] Zentralbl Gynakol. 2004 Feb;126(1):36-40 [14981568.001]
  • [Cites] J Clin Pathol. 1978 Feb;31(2):116-24 [632354.001]
  • [Cites] Acta Cytol. 1996 Jul-Aug;40(4):729-33 [8693894.001]
  • [Cites] Acta Cytol. 1981 May-Jun;25(3):267-71 [6942617.001]
  • [Cites] Acta Cytol. 1985 Jul-Aug;29(4):650-1 [3861059.001]
  • [Cites] Minerva Chir. 1991 Mar 15;46(5):215-9 [2041612.001]
  • (PMID = 21938184.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3168005
  • [Keywords] NOTNLM ; Breast cancer / fine needle aspiration cytology / squamous cell carcinoma
  •  go-up   go-down


80. Rong BG, Chen WL, Ding YP, Xie G, Chen Y, Wang TD: [Surgical approaches to the skull base neoplasms]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Apr;40(4):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven surgical approaches including midfacial degloving, frontal coronal discission, nasal eversion, maxillary swing, partial maxillary resection, total resection of orbit, mandibular swing, combination of front, temple, preauricular, post aureum, neck, and transoral approaches were used to resect the tumor which involved fossae pterygopalatine, paranasal sinuses, nasopharynx, antero, meso and posterobasilar region, lobi frontalis and lobi temporalis of cerebrum.
  • In 29 patients with benign tumor including 11 cases of meningioma, 3 cases of chondroma, 1 case of hemangio-meningioma, 1 case of cavernous hemangioma, 2 cases of osteodysplasia fibromas, 9 cases of neurofibroma, 1 case of glomus jugular tumor, 1 case of neurilemmoma, 19 have survived over 5 years and the longest one has survived over 8 years.
  • For 50 patients with malignant tumor including 3 cases of well-differentiated squamous cell carcinoma, 17 cases of moderately differentiated squamous cell carcinoma, 11 cases of poorly differentiated squamous cell carcinoma, 1 case of undifferentiated carcinoma, 2 cases of chondrosarcoma, 5 cases of canceration of papilloma, 2 cases of adenocarcinoma, 1 case of esthesioneuroblastoma, 2 cases of malignant fibrohistiocytoma, 1 case of fibrosarcoma, 2 cases of malignant mixed tumour, 3 cases of sarcoma survival rates of 3 and 5 years were 59.2% (29/49), 38.5% (10/26) respectively.
  • CONCLUSION: In order to resect the tumor completely and reduce the complication and malformation as far as possible, different surgical approaches must be designed according to the pathological changes characters and involved area,and the surgeon should select the shortest approach, avoid to damage the important neurovascular structure, and resect the tumor through the natural anatomy space by the shelter incision.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008265.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


81. Dennis MM, Ehrhart N, Duncan CG, Barnes AB, Ehrhart EJ: Frequency of and risk factors associated with lingual lesions in dogs: 1,196 cases (1995-2004). J Am Vet Med Assoc; 2006 May 15;228(10):1533-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant tumors accounted for 64% of lingual neoplasms and included melanoma, squamous cell carcinoma, hemangiosarcoma, and fibrosarcoma.
  • Females of all breeds and Poodles, Labrador Retrievers, and Samoyeds were more likely to have squamous cell carcinomas.
  • Benign neoplasms included squamous papilloma, plasma cell tumor, and granular cell tumor.
  • Small-breed dogs, especially Cocker Spaniels, were at increased risk for plasma cell tumors.

  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16677121.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Miyazaki Y, Ikeda K, Uemura Y, Maehara M, Ohmura N, Sawada S: Non-necrotic invasive squamous cell carcinoma associated with an inverted papilloma: MRI features. Radiat Med; 2006 Feb;24(2):143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-necrotic invasive squamous cell carcinoma associated with an inverted papilloma: MRI features.
  • This tumor can be divided into 2 types, those with and those without gross central necrosis.
  • In our case, the tumor did not have any gross central necrosis, and MRI showed convoluted cerebriform patterns.
  • We found that MRI is unable to distinguish malignant and benign regions in a central mass with no gross necrosis, since this lesion does not alter the basic morphological pattern of inverted papilloma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging. Nose Neoplasms / pathology. Papilloma, Inverted / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed


83. Atalay B, Soluk M, Brkić A, Emes Y, Cetin O, Olgac V: Desmoplastic ameloblastoma. J Craniofac Surg; 2009 Nov;20(6):2256-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastoma is a rare benign odontogenic epithelial tumor characterized by abnormal cell growth, which easily infiltrates and destroys surrounding bony tissues.
  • Its histopathologic variant characterized by extensive squamous metaplasia, islands of tumor cells, and sometimes keratin formation is known as desmoplastic acanthomatous ameloblastoma.The aim of this report was to present an unusual case of symphysis located desmoplastic acanthomatous ameloblastoma in a 56-year-old female patient, who was experiencing laryngeal carcinoma 2 years ago.
  • [MeSH-minor] Carcinoma, Squamous Cell / surgery. Female. Humans. Laryngeal Neoplasms / surgery. Middle Aged. Tooth Extraction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934686.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. ZHANG Y, LI M, LIU Y, HAN N, ZHANG K, XIAO T, CHENG S, GAO Y: [ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi; 2010 Dec;13(12):1089-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients].
  • BACKGROUND AND OBJECTIVE: proper tumor markers are useful to diagnosis, prognosis and treatment for lung cancer.
  • The aim of this study is to examine the levels of alpha-enolase (ENO1) protein in the tumor tissues and peripheral plasma samples obtained from non-small cell lung cancer (NSCLC) patients, and evaluate its potential clinical significance.
  • METHODS: the ENO1 protein levels in the tumor tissues and corresponding normal tissues from 16 cases of lung squamous cell carcinoma were analyzed by Western blot.
  • The ENO1 protein levels in the plasma samples from 42 healthy individuals, 34 patients with lung benign disease and 84 patients with NSCLC were measured by double antibody sandwich enzyme-linked immunosorbent assay.
  • RESULTS: for 87.5% (14/16) of the patients with lung squamous cell carcinoma, the ENO1 protein level in the tumor tissues was higher than that in the corresponding normal lung tissues.
  • The ENO1 protein level in the plasma of NSCLC patients was significantly higher than that in the plasma of healthy individuals (P=0.031) and patients with lung benign disease (P=0.019).
  • Furthermore, the ENO1 protein level was significantly higher in the plasma of patients with lung adenocarcinoma than that of patients with lung squamous cell carcinoma.
  • CONCLUSIONS: the elevated levels of ENO1 protein in the tumor tissues and the plasma samples from NSCLC patients indicate ENO1 may be a candidate biomarker of lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / metabolism. DNA-Binding Proteins / blood. DNA-Binding Proteins / metabolism. Phosphopyruvate Hydratase / blood. Phosphopyruvate Hydratase / metabolism. Tumor Suppressor Proteins / blood. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159241.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 4.2.1.11 / ENO1 protein, human; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


85. Colella G, Tozzi U, Pagliarulo V, Bove P: Warthin tumor: a potential source of diagnostic error. J Craniofac Surg; 2010 Nov;21(6):1978-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warthin tumor: a potential source of diagnostic error.
  • PURPOSE: Warthin tumor, also known as papillary cystadenoma lymphomatosum, is a fairly common tumor.
  • There has been much interest in this tumor because of its typical and intriguing morphologic features: the association of benign-looking lymphoid and epithelial components and its frequent occurrence in the intraparotid or periparotid lymph nodes.
  • Moreover, multifocal and/or bilateral Warthin tumors have been reported, and malignant transformation of Warthin tumor and its association with other malignancies have been documented.
  • Warthin tumor can sometimes be confused with other pathologic lesions because of symptoms and signs that accompany the disease, so it could be treated as other pathologic lesions.
  • The first one had a differentiated squamous cell carcinoma, no lymph node metastasis, and a Warthin tumor of the left parotid gland.
  • RESULTS AND CONCLUSIONS: The aim of this study was to evaluate the clinical and histopathologic features of 3 cases where clinical presentation of a Warthin tumor lies in the possible errors in diagnosis and decision making and not least in the management of the patient.
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Male. Maxillary Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Paraproteinemias / diagnosis. Parotid Diseases / diagnosis. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119475.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


86. Laaksonen M, Suojanen J, Nurmenniemi S, Läärä E, Sorsa T, Salo T: The enamel matrix derivative (Emdogain) enhances human tongue carcinoma cells gelatinase production, migration and metastasis formation. Oral Oncol; 2008 Aug;44(8):733-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the effects of EMD on human tongue squamous cell carcinoma (HSC-3) cells in vitro and in vivo.
  • EMD also slightly induced the MMP-2 and -9 production from benign human mucosal keratinocytes (HMK).
  • The migration of both cell lines was inhibited by a selective cyclic anti-gelatinolytic peptide CTT-2.
  • EMD had no effect on HSC-3 cell proliferation or apoptosis and only a limited effect on cell attachment to various extracellular matrix components.
  • [MeSH-major] Amelogenin / pharmacology. Carcinoma, Squamous Cell / enzymology. Dental Enamel Proteins / adverse effects. Tongue Neoplasms / enzymology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Movement / drug effects. Cell Proliferation / drug effects. Enzyme Induction. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Matrix Metalloproteinase Inhibitors. Mice. Tumor Cells, Cultured. Wound Healing / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18061521.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amelogenin; 0 / Dental Enamel Proteins; 0 / Matrix Metalloproteinase Inhibitors; 0 / enamel matrix proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


87. Lin J, Iannettoni MD: Transhiatal esophagectomy. Surg Clin North Am; 2005 Jun;85(3):593-610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most important determinants of survival appear to be the biologic behavior of the tumor and the stage at the time of resection rather than the operative approach, and esophageal carcinoma will likely require systemic therapy for a cure.
  • Transhiatal esophagectomy has been used increasingly in the resection of benign and malignant disease, and has several potential advantages over transthoracic esophagectomy, including significantly decreased respiratory complications and mediastinitis due to the avoidance of thoracotomy and intrathoracic anastomosis.
  • Survival after THE is also equivalent to or better than that seen after transthoracic esophagectomy, and transhiatal esophagectomy should be considered in all patients requiring esophagectomy for benign or malignant disease.
  • [MeSH-minor] Anastomosis, Surgical. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Humans. Minimally Invasive Surgical Procedures / methods. Postoperative Care. Postoperative Complications. Preoperative Care. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15927654.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


88. Jansen AP, Camalier CE, Colburn NH: Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res; 2005 Jul 15;65(14):6034-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.
  • Programmed cell death 4 (Pdcd4) is a novel repressor of in vitro transformation.
  • To ascertain whether Pdcd4 suppresses tumor development in vivo, we have generated transgenic mice that overexpress Pdcd4 in the epidermis (K14-Pdcd4).
  • These results extend to an in vivo model the observations that Pdcd4 inhibits both translation initiation and AP-1 activation while decreasing benign tumor development and malignant progression.
  • [MeSH-major] Carcinoma, Squamous Cell / prevention & control. Papilloma / prevention & control. RNA-Binding Proteins / physiology. Skin Neoplasms / prevention & control


89. Wilson ML, Elston DM, Tyler WB, Marks VJ, Ferringer T: Dense lymphocytic infiltrates associated with non-melanoma skin cancer in patients with chronic lymphocytic leukemia. Dermatol Online J; 2010;16(3):4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell carcinomas and squamous cell carcinomas in these patients may have an associated dense peritumoral leukemic infiltrate.
  • This infiltrate can lead to the diagnosis of CLL and may also obscure tumor margins and pose a challenge in the assessment of perineural tumor spread.
  • Immunohistochemical stains are useful in distinguishing leukemic B-cell infiltrates from tumor-reactive T-cell infiltrates.
  • Leukemic cells of CLL are CD20+/CD23+/CD5+/CD43+/CD3-, whereas benign reactive infiltrates are composed of CD20-/CD23-/CD5+/CD43+/CD3+ T-cells.
  • Given the paucity of symptoms in early stages of CLL, a dense lymphoid infiltrate surrounding a cutaneous neoplasm may serve as the first indication of CLL.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemic Infiltration / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Antigens, CD43 / analysis. Antigens, CD5 / analysis. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Receptors, IgE / analysis. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20233561.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD43; 0 / Antigens, CD5; 0 / Biomarkers, Tumor; 0 / Receptors, IgE
  •  go-up   go-down


90. Driss M, Limaiem F, Mrad K, Charfi L, Abbes I, Sassi S, Hechiche M, Saadi A, Ben Romdhane K: [Malignant degeneration of benign cystic teratoma of the ovary with synchronous mediastinal teratoma. A case report]. Rev Med Interne; 2009 Apr;30(4):369-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant degeneration of benign cystic teratoma of the ovary with synchronous mediastinal teratoma. A case report].
  • [Transliterated title] Association synchrone d'un tératome de l'ovaire cancérisé associé à un tératome du médiastin. A propos d'un cas.
  • Squamous cell carcinoma arising in mature cystic teratoma of the ovary is an uncommon complication occurring usually in elderly woman.
  • While ovary tumor was symptomatic, mediastinal teratoma was an incidental finding.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722037.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, Paudyal B, Iida Y, Hanaoka H, Ishikita T, Nakasone Y, Negishi A, Mogi K, Endo K: Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med; 2007 Feb;21(2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.
  • METHODS: This study included 36 patients (16 males, 20 females; 31-90 years old) with untreated malignant tumors (34 squamous cell carcinoma, one mucoepidermoid carcinoma, one rhabdomyosarcoma) and seven patients (five males, two females; 32-81 years old) with benign lesions.
  • PET images were rated according to the contrast of tumor uptake as compared with background, and were statistically analyzed.
  • RESULTS: The mean SUV of the malignant lesions were significantly higher than those of the benign lesions in both FMT-PET (2.62 +/- 1.58 vs. 1.20 +/- 0.30, p < 0.01) and FDG-PET (9.17 +/- 5.06 vs. 3.14 +/- 1.34, p < 0.01).
  • In 27 of 36 patients, FMT-PET had better contrast of malignant tumor visualization to the surrounding normal structures by visual assessment (p < 0.005, binomial proportion test).

  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17424980.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / O-(18F)fluoromethyl-L-tyrosine; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


92. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS: Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther; 2009 May;8(10):907-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Cub and Sushi Multiple Domains-1 (CSMD1) is a tumor suppressor gene on 8p23.2, where allelic loss is both frequent and associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC).
  • To understand the extent of CSMD1 aberrations in vivo, we characterized 184 primary tumors from the head and neck, lung, breast and skin for gene copy number and analyzed expression in our HNSCCs and lung squamous cell carcinomas (SCCs).
  • We detected loss of CSMD1 in a large proportion of HNSCCs (50%), lung (46%) and breast cancers (55%), and to a lesser extent in cutaneous SCCs (29%) and basal cell carcinomas (BCCs, 17%) using array-based comparative genomic hybridization (aCGH).
  • CSMD1 expression was decreased in tumors compared to adjacent benign tissue (65%, 13/20) and was likely due to gene loss in 45% of cases (9/20).
  • [MeSH-minor] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Chromosome Deletion. Comparative Genomic Hybridization. DNA, Neoplasm / analysis. Female. Gene Dosage. Gene Expression. Humans. Loss of Heterozygosity. Mouth Neoplasms / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism


93. Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z: An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol; 2009 Apr;33(4):521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IMP3 is an oncofetal protein and has been demonstrated to be associated with aggressive tumor behavior.
  • Expression of IMP3 was not found in adjacent benign squamous and glandular mucosa.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / diagnosis. Neoplasm Proteins / metabolism. Precancerous Conditions / diagnosis. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Cell Transformation, Neoplastic. Esophagus / metabolism. Esophagus / pathology. Esophagus / surgery. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Mucous Membrane / metabolism. Mucous Membrane / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047899.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


94. Liang H, Wu H, Giorgadze TA, Sariya D, Bellucci KS, Veerappan R, Liegl B, Acs G, Elenitsas R, Shukla S, Youngberg GA, Coogan PS, Pasha T, Zhang PJ, Xu X: Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. Am J Surg Pathol; 2007 Feb;31(2):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The initial test series were composed of a total of 93 cases including 32 primary skin adnexal carcinomas, 46 benign primary adnexal tumors, and 15 cutaneous metastatic adenocarcinomas.
  • We found that variable D2-40 reactivity was seen in all of the primary cutaneous carcinomas including sebaceous carcinomas (10/10), squamous cell carcinomas (10/10), porocarcinomas (4/4), trichilemmal carcinomas (4/4), skin adnexal carcinomas not otherwise specified (4/4), and in the majority of benign skin adnexal tumors.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / pathology. Membrane Glycoproteins / metabolism. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255777.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human
  •  go-up   go-down


95. Wang JH, Lee JH, Han JH, Lee BJ, Jang YJ: Contralateral maxillary sinus lesions in patients with nasal cavity and/or paranasal sinus carcinoma: analysis of computed tomography findings. Ann Otol Rhinol Laryngol; 2008 Dec;117(12):909-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both masses were diagnosed histologically as poorly differentiated squamous cell carcinoma.
  • Twenty-three of the 32 patients with benign lesions were included in the follow-up CT analysis, ranging from 24 to 108 months (mean, 45 months).
  • During the follow-up period, no definite abnormality suggesting tumor development in the contralateral maxillary sinus was detected.
  • CONCLUSIONS: Even though most contralateral maxillary sinus lesions are benign and the incidence of bilateral maxillary sinus carcinoma is very low, second primary maxillary sinus carcinoma should be kept in mind in the differential diagnosis of contralateral maxillary sinus lesions in patients with nasal cavity and/or paranasal sinus carcinoma.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19140537.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Gong Y, Jalali M, Staerkel G: Fine needle aspiration cytology of a thyroid metastasis of metaplastic breast carcinoma: a case report. Acta Cytol; 2005 May-Jun;49(3):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metaplastic breast carcinoma is defined as mesenchymal and/or squamous cell components associated with ductal carcinoma.
  • Because of the heterogeneous nature of this tumor, cytologic interpretation on fine needle aspirates can be quite challenging.
  • This is especially true of metastatic lesions of this rare tumor type.
  • The aspirate specimen was composed of scant, highly atypical epithelial cells in a background of an abundant chondromyxoid matrix and scattered, benign follicular cells.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966298.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Brouha XD, Tromp DM, de Leeuw JR, Hordijk GJ, Winnubst JA: Laryngeal cancer patients: analysis of patient delay at different tumor stages. Head Neck; 2005 Apr;27(4):289-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal cancer patients: analysis of patient delay at different tumor stages.
  • Only tumor site was significantly associated with patient delay.
  • Medical attention was postponed because symptoms were interpreted as innocuous/benign or the symptom was thought not to be serious enough.
  • [MeSH-major] Carcinoma, Squamous Cell / psychology. Laryngeal Neoplasms / psychology. Patient Acceptance of Health Care / psychology
  • [MeSH-minor] Aged. Appointments and Schedules. Attitude to Health. Cohort Studies. Common Cold / psychology. Female. Glottis / pathology. Health Behavior. Hoarseness / psychology. Humans. Lymphatic Metastasis / pathology. Male. Neoplasm Staging. Voice Disorders / psychology

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668927.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Panizzon RG: [Dermatologic radiotherapy]. Hautarzt; 2007 Aug;58(8):701-10, quiz 711
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another important parameter is the half-value depth which should correspond to the depth of the tumor below the skin surface.
  • Indications for radiotherapy of malignant skin tumors include basal cell carcinoma, squamous cell carcinoma, severe actinic keratoses, lentigo maligna, lentigo maligna melanoma, Merkel cell carcinoma, and Kaposi sarcoma, as well as T- and B-cell lymphomas.
  • The most common benign lesions where radiotherapy may be indicated are eczemas, psoriasis, and keloids, but its use should be carefully weighed in these settings.
  • [MeSH-minor] Eczema / radiotherapy. Humans. Keloid / radiotherapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Cutaneous / radiotherapy. Palliative Care. Psoriasis / radiotherapy. Radiotherapy Dosage. Sarcoma, Kaposi / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639284.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Ruddell A, Kelly-Spratt KS, Furuya M, Parghi SS, Kemp CJ: p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene; 2008 May 15;27(22):3145-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ability of tumor cells to metastasize is increasingly viewed as an interaction between the primary tumor and host tissues.
  • Deletion of the p19/Arf or p53 tumor suppressor genes accelerates malignant progression and metastatic spread of 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced squamous cell carcinomas, providing a model system to address mechanisms of metastasis.
  • Here, we show that benign pre-metastatic papillomas from wild-type mice trigger lymphangiogenesis within draining lymph nodes, whereas there is no growth of primary tumor lymphatic vessels.
  • The extent of accumulation of B cells within the tumor-draining lymph nodes of wild-type mice predicted the level of lymph node lymphangiogenesis and metastatic potential.
  • Arf or p53 deficiency strongly accelerated lymph node immune cell accumulation, in a manner that was associated with the extent of lymph node lymphatic sinus growth.
  • This immune cell accumulation and lymph node lymphangiogenesis phenotype identifies host anti-tumor responses that could drive metastatic spread of cancers via the lymphatics.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cyclin-Dependent Kinase Inhibitor p16 / physiology. Lymph Nodes / physiology. Lymphangiogenesis / genetics. Lymphatic Metastasis. Skin Neoplasms / pathology. Tumor Suppressor Protein p53 / physiology
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. B-Lymphocytes / pathology. Cell Proliferation. Chemotaxis, Leukocyte / genetics. Macrophages / pathology. Mice. Mice, Transgenic. Neovascularization, Pathologic / genetics. Tetradecanoylphorbol Acetate. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059331.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA68328; United States / NCI NIH HHS / CA / R01-CA99517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


100. Santini M, Fiorello A, Mansi L, Rambaldi PF, Vicidomini G, Busiello L, Messina G, Nargi P: The role of technetium-99m hexakis-2-methoxyisobutyl isonitrile in the detection of neoplastic lung lesions. Eur J Cardiothorac Surg; 2009 Feb;35(2):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, semiquantitative analysis was made by calculating tumor/contralateral normal lung ratio (T/N).
  • RESULTS: Sixty patients had a malignant lesion: 44 squamous cell carcinoma, 7 adenocarcinomas, 4 large cell carcinoma, 1 small cell lung cancer, and 4 metastases.
  • Nineteen patients had a benign disease.
  • The mean size+/-standard deviation of benign nodules was 3.3+/-1.71 cm (range 2-6 cm). (99m)Tc-MIBI SPECT delineated focal lesions with an increase in tracer accumulation in 55/60 malignant lesions; in 5/60 malignant lesions was negative.
  • In patients with neoplastic lesion, the mean T/N ratio value+/-standard deviation was 1.72+/-0.35 whereas in patients with benign lesions was 1.14+/-0.25.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Tomography, Emission-Computed, Single-Photon / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996706.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down






Advertisement